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Abstract 
Members of the protein superfamily of tetraspanins are best defined by a simple 
structure comprising four transmembrane domains, two extracellular loops of unequal 
size, and short cytoplasmic regions. Despite their small size, tetraspanins are able to 
participate in multiple functions, as diverse as B cell activation, cancer metastasis, and 
viral infection. To compensate for a lack of intrinsic enzymatic activity, tetraspanins have 
gained the fascinating ability of associating with numerous different proteins. In addition, 
tetraspanins interact with each other forming a network on the plasma membrane: the 
tetraspanin web. In this way, functionally related proteins binding to different 
tetraspanins can be brought into close vicinity, thereby enhancing signaling pathways. 
The tetraspanin web is a dynamic environment and its regulation has grasped the 
attention of several research groups in the past few years. Particularly, several 
tetraspanins have been found to be palmitoylated, a post-translational modification 
attaching a palmitic acid to cysteine residues in a reversible manner. Palmitoylation is 
thought to be important for the integrity of the tetraspanin web. 
We examined the effect of disrupting putative palmitoylation sites on the 
tetraspanin CD81 by mutating its juxtamembrane cysteines. By flow cytometry, we 
observed a decrease in the detection of mutant CD81 at the cell surface. This was not due 
to defects in protein trafficking or antibody affinity, and might reflect an abnormal CD81 
distribution in a membrane environment that prevents the exposure of the epitope 
recognized by the CD81 antibody. Immunoblotting analysis revealed a novel CD81 
processing event that was impaired in the mutant CD81 proteins compared to wild-type. 
Finally, co-immunoprecipitation assays showed a reduction in binding of tetraspanin 
CD9 and Ig superfamily member EWI-2 to mutant CD81. Taken together, these results 
suggest the importance of juxtamembrane cysteines (via palmitoylation or protein 
conformational changes) in protein interactions of CD81 within the tetraspanin web. 
Although 33 tetraspanins are expressed in humans, less than half of them have 
been well studied. Among the “orphan” tetraspanins awaiting further examination is 
 Tspan-2. Here, we provide the first elements for the characterization of mammalian 
Tspan-2 by investigating expression patterns, N-glycosylation status, and association 
with other tetraspanins. 
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Abstract 
Members of the protein superfamily of tetraspanins are best defined by a simple 
structure comprising four transmembrane domains, two extracellular loops of unequal 
size, and short cytoplasmic regions. Despite their small size, tetraspanins are able to 
participate in multiple functions, as diverse as B cell activation, cancer metastasis, and 
viral infection. To compensate for a lack of intrinsic enzymatic activity, tetraspanins have 
gained the fascinating ability of associating with numerous different proteins. In addition, 
tetraspanins interact with each other forming a network on the plasma membrane: the 
tetraspanin web. In this way, functionally related proteins binding to different 
tetraspanins can be brought into close vicinity, thereby enhancing signaling pathways. 
The tetraspanin web is a dynamic environment and its regulation has grasped the 
attention of several research groups in the past few years. Particularly, several 
tetraspanins have been found to be palmitoylated, a post-translational modification 
attaching a palmitic acid to cysteine residues in a reversible manner. Palmitoylation is 
thought to be important for the integrity of the tetraspanin web. 
We examined the effect of disrupting putative palmitoylation sites on the 
tetraspanin CD81 by mutating its juxtamembrane cysteines. By flow cytometry, we 
observed a decrease in the detection of mutant CD81 at the cell surface. This was not due 
to defects in protein trafficking or antibody affinity, and might reflect an abnormal CD81 
distribution in a membrane environment that prevents the exposure of the epitope 
recognized by the CD81 antibody. Immunoblotting analysis revealed a novel CD81 
processing event that was impaired in the mutant CD81 proteins compared to wild-type. 
Finally, co-immunoprecipitation assays showed a reduction in binding of tetraspanin 
CD9 and Ig superfamily member EWI-2 to mutant CD81. Taken together, these results 
suggest the importance of juxtamembrane cysteines (via palmitoylation or protein 
conformational changes) in protein interactions of CD81 within the tetraspanin web. 
Although 33 tetraspanins are expressed in humans, less than half of them have 
been well studied. Among the “orphan” tetraspanins awaiting further examination is 
 Tspan-2. Here, we provide the first elements for the characterization of mammalian 
Tspan-2 by investigating expression patterns, N-glycosylation status, and association 
with other tetraspanins. 
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CHAPTER 1 - The Tetraspanin Web 
Four transmembrane domains, two extracellular loops, one conserved motif (Cys-
Cys-Gly), and several additional cysteine residues in the large extracellular loop: these 
are the essential structural features that define members of the tetraspanin superfamily of 
proteins. Tetraspanins are ubiquitously found in most, if not all, multicellular organisms. 
Despite a seemingly simple structure with relatively short extra- and intracellular 
domains, tetraspanins are able to undertake a surprisingly broad array of functions in 
processes as diverse as the immune system, virus infectivity, viability of the retina, and 
cancer metastasis. How are tetraspanins able to achieve such functional diversity? Since 
their discovery in the early 1990’s, the advancements made in the tetraspanin field have 
revealed a fascinating picture where tetraspanins and their associated proteins form a 
dynamic network at the plasma membrane, known as the tetraspanin web. Depending on 
the proteins they interact with, tetraspanins can influence several processes. This review 
will explore the tetraspanin web and its multiple cellular roles. 
The building blocks: the tetraspanins 
What are tetraspanins? 
A tetraspanin protein can be divided into four major structural domains: the large 
extracellular loop (LEL), the small extracellular loop (SEL), the transmembrane domains 
(TMs), and the cytoplasmic regions (Fig. 1.1). The structure of tetraspanins is tightly 
packed resulting in an overall cylindrical shape that sticks out of the lipid bilayer by 3 to 
5 nm1, 2. 
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Figure 1.1 Basic tetraspanin structure and domains 
Large extracellular loop 
The LEL has received most of the attention since early findings reported it to be 
crucial for interactions with other proteins. This interest led to the X-ray analysis of 
tetraspanin CD81 LEL by Kitadokoro et al.3. This study revealed the LEL as a 
mushroom-shaped structure with two main regions: the so-called stalk region formed by 
helices A and E, and the head subdomain containing helices B, C, and D. The sequence 
corresponding to the head subdomain is highly variable among members of the 
tetraspanin superfamily except for the presence of a CCG motif in addition to two to six 
cysteines. These residues are distinctive of tetraspanins and have a role in stabilizing the 
LEL via disulfide bonds3. The significance of these covalent bonds is illustrated by the 
lack of binding of most tetraspanin-specific monoclonal antibodies under reducing 
conditions4, 5. This observation also underscores the relevance of the LEL since it is the 
target of most of these antibodies6, 7. 
The head subdomain region plays a fundamental role in protein-protein 
interactions. Because of the hypervariability of its sequence, it can confer great 
specificity in interactions with a particular tetraspanin. Entry of hepatitis C virus (HCV) 
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is mediated by this region of CD818. Residue F186 is particularly important for this 
function as its mutation inhibits CD81 binding to HCV glycoprotein E24. Tetraspanin 
CD151 also depends on its LEL to interact with the α3 subunit of integrin α3β16. The LEL 
of another member of the superfamily, CD9, is required for binding to HB-EGF and for 
facilitating sperm-egg fusion9, 10. 
The stalk of the LEL has been linked to homodimerization of CD813. However, 
further modeling of the full CD81 molecule by Seigneuret suggested that this region is 
mostly hidden by the SEL1. 
The LEL is also the region where N-glycosylation sites are mostly found. These 
sites vary among tetraspanins providing another level of specificity in this domain7. Some 
tetraspanins do not have predicted glycosylation sites (CD81), and in the case of CD9, the 
sites are located in the SEL7. 
Small extracellular loop 
Less is known about the tetraspanin SEL. It is thought to have a role in supporting 
the proper structure of the LEL2. 
Transmembrane domains 
The importance of the transmembrane domains was first highlighted by Cannon 
and Cresswell in a report where they found that a CD82 construct lacking the first TM 
domain was unable to exit the endoplasmic reticulum (ER)5. Surprisingly, co-expression 
with a separate construct containing TM1 restored proper transport to the plasma 
membrane, indicating a strong interaction between TM domains and a role in tetraspanin 
protein trafficking5. CD9 constructs lacking the TM2-TM3 region or containing only the 
TM3-LEL-TM4 region were unable to efficiently reach the cell surface11. The TM1-TM3 
region was also found to be important for proper localization of CD1516. 
The transmembrane domains are required to ensure correct folding of the LEL. 
Indeed, deletion of TM domains in the previously mentioned CD9 constructs also 
prevents recognition of the LEL by conformational monoclonal antibodies11. 
Several polar residues embedded in the transmembrane domains are highly 
conserved among tetraspanins (N in TM1 and E/Q in TM3 and TM4)7. These residues 
have been proposed to be involved in inter-helical interactions between TM domains via 
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hydrogen bonding, thereby allowing more efficient packing of TM domains1, 2. Mutation 
of TM3 residue E102 in the tetraspanin uroplakin Ib prevents its export to the cell 
surface12. Substitutions of other TM polar amino acids in CD81 resulted in the inhibition 
of HCV entry13. 
Recent evidence supports an additional role for TM domains in tetraspanin 
dimerization and interaction with other proteins. CD81 TM1 is required for proper 
transport of its binding partner CD19 to the plasma membrane14. Homodimerization of 
CD9 was found to depend on its TM domains15. In addition, the primary interaction 
between tetraspanin uroplakins and their non-tetraspanin partners also requires the LEL 
and TM domains2. 
Cytoplasmic regions 
Despite their short length, the cytoplasmic regions of tetraspanins can participate 
in various functions. Tetraspanin subcellular localization might be regulated by 
interaction with clathrin-dependent adaptor proteins. A specific tyrosine motif in the C-
terminal domain of several tetraspanins is known to bind to adaptor protein complexes 
(YXXΦ where X is any amino acid and Φ is a bulky hydrophobic residue)16. Distribution 
of CD63 to intracellular vesicles is mediated by binding of AP-3 to this tyrosine motif17. 
CD151 internalization and antibody-stimulated CD82 endocytosis are impaired when this 
motif is mutated16, 18. However, some tetraspanins might not require this motif for proper 
localization, suggesting that other mechanisms are in place16. Moreover, syntenin-1 has 
been shown to bind the C-terminal domain of CD63 and influence its internalization in an 
adaptor protein-independent way19. 
The cytoplasmic regions are also involved in protein interactions. Several 
tetraspanins are able to interact specifically with important signaling molecules: 
phosphatidylinositol-4 kinase (CD9, CD63, CD81, CD151, and A15), protein kinase C 
(CD9, CD53, CD81, CD82, and CD151), 14-3-3 (CD81), and G protein subunits (CD9 
and CD81)20-23. The C-terminal tail of CD81 also associates with ERM (ezrin-radixin-
moesin) proteins, providing a bridge between the tetraspanin web and the cytoskeleton24. 
Finally, the cytoplasmic regions are the sites of palmitoylation. Several 
tetraspanins have already been shown to be labeled with palmitic acid, and more 
members of the superfamily are likely to join the list since most tetraspanins have 
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juxtamembrane cysteines, which are potential palmitoylation sites25. Mutation of these 
cysteines and use of a specific inhibitor have resulted in alterations in the organization of 
the tetraspanin web (described below, p22). 
Where are tetraspanins found? 
Expression in organisms throughout the evolutionary tree 
From simple eukaryotic organisms such as sponges and fungi to arthropods and 
vertebrates, tetraspanins are ubiquitously found across the evolutionary tree. These 
proteins seem to be mostly specific to multicellular organisms as best illustrated by their 
presence in several multicellular pathogenic fungi whereas none were found in the 
genomes of 17 single-celled fungi species (including Saccharomyces cerevisiae)26. 
Perhaps due to historical reasonstetraspanins were first discovered in mice and 
humans—most of the knowledge in this field has been largely concentrated on 
mammalian tetraspanins (33 members are expressed in humans), and this bias is reflected 
throughout this review. Although Drosophila melanogaster has 37 tetraspanins, only 
three of them have been studied: Late bloomer (role in neuromuscular junction 
formation), Sunglasses (light-induced retinal degeneration), and Tsp68C (hemocyte 
proliferation)27-29. Interestingly, the fruit fly genome has a cluster of 18 tetraspanins in the 
42E region of the second chromosome30. When half of the genes in this cluster were 
deleted, flies developed normally, indicating a strong compensatory mechanism by other 
tetraspanins, a property that seems to be common to tetraspanins in general31. This 
particular cluster is specific to insects in the fly branch as other arthropods, such as the 
mosquito Anopheles gambiae and the honey bee Apis mellifera, do not encode it in their 
genomes26. Research on Caenorhabditis elegans has been limited to one of its 20 
members, TSP-15, and its role in the maintenance of the hypodermis32. Several reports 
from Lebrun’s group have shown the relevance of tetraspanins in the pathogenicity of 
several fungi including Magnaporthe grisea, an economically important rice pathogen33-
35. Without the tetraspanin Pls1, M. grisea is unable to penetrate the host plant tissue34. 
The tetraspanin D76 in the moth Manduca sexta plays a role in innate immune responses 
through binding to an integrin on hemocytes36. Mosquito Aedes albopictus cells 
upregulate the tetraspanin C189 when infected by dengue virus37. Even in the primitive 
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sponges, a tetraspanin is thought to be a component of cell junctions in the epithelium38. 
Therefore, it is likely that tetraspanins emerged from duplications of a common ancestor 
acquired during the unicellular-to-multicellular transition of eukaryotes26. It is interesting 
to note that even several plants (including Arabidopsis thaliana) possess tetraspanin-like 
proteins (lacking the CCG motif in the LEL)26. 
Expression in multiple tissues 
Tetraspanins are not only found in most organisms, they are also found in a wide 
variety of tissues. In mammals, almost all cell types, except erythrocytes, express 
multiple members of the tetraspanin superfamily, an important factor for the building of 
the tetraspanin web as described in the next section39. However, tissue distribution of 
individual tetraspanins can vary substantially. Tetraspanins CD9, CD63, CD81, CD82, 
and CD151 are characterized by a wide expression pattern7, 39. Other tetraspanins are 
limited to specific organs or tissues: uroplakins Ia and Ib are exclusively expressed in the 
bladder because of their unique function in the assembly of the urothelial plaques; ROM-
1 and peripherin-2 expression is restricted to the outer segment discs of rod photoreceptor 
cells; and CD37 and CD53 are specific to immune cell types12, 40, 41. Additionally, this 
wide distribution is also present in Drosophila melanogaster; a study of 35 tetraspanins 
showed great variation in their expression patterns among tissue progenitors at the 
embryonic stage, indicating this might be a common aspect of tetraspanins across 
organisms31. 
Subcellular expression 
The diversity in tetraspanin expression distribution at the tissue level is also 
observed in their subcellular localization. Although tetraspanins are generally found at 
the plasma membrane, in several cases, they are enriched in various intracellular 
compartments. The best example is CD63; because of its tyrosine-sorting motif 
(described above, p4), it is commonly found in the lysosomes of multiple cell types. 
CD63 is also present in specialized vesicles in some cell types: dense and alpha-granules 
(platelets), azurophil granules (neutrophils), cytotoxic T lymphocyte granules, and 
Weibel-Palade bodies (endothelial cells)42-46. Together with CD37, CD81, and CD82, 
CD63 is also distributed to MHC class II-enriched multivesicular bodies (MIICs) in B 
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cells47. Multivesicular bodies are formed by the invagination of the limiting membrane, 
and in antigen-presenting cells, they can traffic to the cell surface and release internal 
vesicles called exosomes. Exosomes are thought to have a role in antigen presentation 
since they carry MHC class II molecules. Several groups have reported the localization of 
tetraspanins in exosomes: in B cells (CD37, CD63, CD81, and CD82), T cells (CD81), 
dendritic cells (CD9), and intestinal epithelial cells (CD9, CD81, and CD82)47-50. CD151 
can also be concentrated in intracellular vesicles in endothelial and hemopoietic cell 
types51, 52. 
Distribution within the plasma membrane can also vary among tetraspanins. 
Highly specialized retinal tetraspanins ROM-1 and peripherin-2 are mostly found in the 
disc rims of rod photoreceptor cells53, 54. Uroplakin tetraspanins are restricted to the 
apical side of the bladder urothelium clustered in highly organized asymmetric unit 
membrane structures (described below, p8)55. Finally, most tetraspanins are thought to be 
found at specific times in specialized plasma membrane compartments called tetraspanin-
enriched microdomains (TEMs), a key component of the tetraspanin web. 
The tetraspanin web 
The interaction with binding partners defines the essence of a tetraspanin. These 
associations are at the root of the tetraspanin web, a term coined to describe the protein 
network of members of the tetraspanin superfamily and their binding partners at the 
plasma membrane56. Assembled to provide proteins some sense of stability within the 
fluid environment of the lipid bilayer, the tetraspanin web can be a challenging concept to 
grasp at first hand. However, it can be simplified by dividing the network into two types 
of interactions. First, at the core of the web, there is the direct and strong binding between 
tetraspanins and their specific partners (primary interactions); and second, indirect 
binding between these primary groups brings the web together (secondary interactions). 
A great example to illustrate the building of such a network is the assembly of uroplakin 
tetraspanins and their binding partners into a bladder-specific epithelial structure called 
the asymmetric unit membrane (AUM). 
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The asymmetric unit membrane: a highly specialized tetraspanin web 
The top-most layer of the bladder epithelium (urothelium) consists of highly 
differentiated cells that are characterized by the presence of plaques covering most of the 
bladder lumen57. These plaques can be seen in electron micrographs as composed of 16-
nm particles organized in a crystal-like hexagonal lattice. Each particle can be divided in 
an inner and an outer ring, each containing six subdomains57, 58. These plaques are 
composed of four different types of proteins: tetraspanin uroplakins UP Ia and Ib, and 
single-transmembrane-domain uroplakins UP II and III59, 60. The protein content of these 
structures results in a thicker outer leaflet of the plasma membrane compared to the inner 
leaflet, a featured implied in the name “asymmetric unit membrane”58. The AUM is 
thought to be important in helping the bladder retain urine without damaging internal 
contents by acting as a permeability barrier61. The assembly of the AUM relies on the 
diverse interactions occurring among uroplakins (Fig. 1.2). The strongest associations are 
between the tetraspanin UP Ia/Ib and their binding partners UP II/III, respectively; they 
can be chemically cross-linked and only stringent detergents can break them apart59. 
These primary interactions are the base of the 16-nm particles by forming the subdomains 
(UP Ia/II in the inner ring and UP Ib/III in the outer ring)2. These subdomains are linked 
together into subunits via binding between the non-tetraspanin uroplakins UP II and III; 
and association between UP Ia and UP II from two neighboring subunits forms the 
particles2. These secondary interactions are weaker and less amenable to cross-linking. 
Finally, a third level of interactions brings together multiple particles into the lattice that 
makes the AUM2. 
By solving the structure of this bladder-specific tetraspanin web, Sun’s group and 
their collaborators have provided a compelling model to the tetraspanin field in general, 
as several features of the AUM are likely to be extrapolated to other tetraspanin 
networks. Indeed, direct and indirect interactions between tetraspanin and their binding 
partners have already been the focus of a numerous studies. 
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Figure 1.2 The asymmetric unit membrane 
This figure depicts the assembly of the AUM by different interactions between 
tetraspanin uroplakins UP Ia/Ib and their respective non-tetraspanin binding partners UP 
II/III (adapted from ref. 2). 
Direct interactions 
One major difference, however, distinguishes the AUM from the classical 
tetraspanin web found in most tissues: whereas the tetraspanin/binding partner interaction 
is solely at the base of the AUM, tetraspanins homodimers are thought to be the central 
element of the tetraspanin web. A detailed study from Hemler’s group analyzed 
tetraspanin homodimers by applying a novel cross-linking technique that takes advantage 
of spontaneous disulfide bonding that can occur between juxtamembrane cysteine 
residues of adjacent tetraspanins62. This cross-linking method, termed “zero-length” as 
compared to the use of chemical cross-linkers with variable arm lengths, allows the 
detection of molecules that are in very close proximity. Homodimers of CD9, CD81, and 
CD151 were found to be cross-linked, implying a direct interaction with themselves62. 
These results led the authors to propose that tetraspanin homodimers are the essential 
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components of the tetraspanin network from which all the other protein interactions are 
assembled62. Supporting this model, tetraspanins peripherin-2 and ROM-1 were also 
shown to form homodimers that could be cross-linked with glutaraldehyde63. 
The second type of primary interactions required to build a tetraspanin web is 
between tetraspanins and their specific binding partners39. Although multiple proteins are 
known to associate with tetraspanins, few of them show a direct interaction. Several 
criteria have been used to qualify proteins as direct binding partners: resistance to 
stringent detergents (Triton X-100, digitonin), ability to be chemically cross-linked, 
and/or high stoichiometry. The binding of CD151 to the integrin α3β1 is a good example 
since it fulfills all these requirements64, 65. Two other tetraspanin/integrin associations 
(CD81/α4β1 and CD151/α6β1) are also highly efficient due to their presence under 
conditions preventing tetraspanin heterodimer formation (lysis with digitonin)65. 
Members of the Ig superfamily can also be found in primary complexes with 
tetraspanins: EWI-2 and EWI-F interact specifically with both CD9 and CD81, and CD19 
depends on its direct association with CD81 for its maturation and functioning in the B 
cell coreceptor14, 66-68. 
Indirect interactions 
The sensitivity to detergents of variable strengths has allowed the detection of the 
several levels characterizing the tetraspanin web. By lysing cells with weaker detergents 
(Brij-97, CHAPS), numerous additional proteins—including other tetraspanins—co-
precipitate with tetraspanins39. For example, integrin α3β1 can be co-precipitated with 
CD9, CD63, and CD81 only under mild conditions; with stringent detergents, only 
CD151 is co-precipitated with this integrin. CD9, CD63, and CD81 associate with α3β1 
indirectly, as part of the tetraspanin web64, 69. These secondary interactions are thought to 
occur via associations among different tetraspanins39. A striking feature of tetraspanins is 
their capacity to bind several other tetraspanins. These interactions, detected mostly 
under mild conditions, have been proposed to be the key elements linking the primary 
complexes together, thus forming the tetraspanin web39. This model illustrates why so 
many different proteins have been discovered in indirect association with tetraspanins, 
including integrins69, Ig superfamily members66, 68, growth factors9, GPCRs23, 
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metalloproteases70, and various signaling molecules20, 21. By bringing these proteins close 
to each other, the tetraspanin web may facilitate signaling pathways, thereby influencing 
various cellular functions (described below, p13)56. The multiple interactions within this 
network are thought to be held in membrane compartments called tetraspanin-enriched 
microdomains.   
Tetraspanin-enriched microdomains 
Membrane microdomains are plasma membrane compartments characterized by a 
high protein:lipid ratio and a lipid content enriched in cholesterol and sphingolipids. The 
best-known examples are lipid rafts; many studies have shown their role in diverse 
signaling pathways such as B cell and T cell activation71, 72. Lipid rafts provide a 
delimited area within the plasma membrane where proteins required for specific 
functions can be recruited. Once considered the only type of membrane 
compartmentalization, lipid rafts are now becoming part of a more extensive list of 
membrane microdomains. The traditional criteria to define a lipid raft rely on its isolation 
method: when cells are lysed with 1% Triton X-100 (TX-100) and analyzed by a sucrose 
gradient, detergent-resistant membranes (DRMs) will float to the upper layers of the 
gradient71. These insoluble complexes contain the lipid rafts. Other methods have been 
used to confirm the existence of these rafts in living cells, but sucrose gradients are still 
commonly used to isolate lipid rafts. The hypothesis that other types of microdomains co-
exist in the plasma membrane was brought to light upon discovering DRMs with 
different properties compared to classical lipid rafts. One example is the tetraspanin-
enriched microdomain (TEM). 
 Because of the multiple associations found in the tetraspanin web under mild 
lysis conditions, several groups tested the idea that this network could be held together 
within membrane microdomains such as lipid rafts. However, several tetraspanins (CD9, 
CD63, CD81, and CD151) were not found in DRMs of cells lysed with TX-100. Instead, 
when a milder detergent (Brij-97) was used, tetraspanins were readily found in the top 
layers of sucrose gradients73, 74. These microdomains are sensitive to the amount of 
cholesterol, as treatment with methyl-β-cyclodextrin (MβCD), a chemical that depletes 
cholesterol from the plasma membrane, reduces the level of tetraspanins in DRMs74, 75. 
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Whereas isolation of lipid rafts is temperature-sensitive (cell lysis needs to be performed 
at 4 ºC), the tetraspanin DRMs remain stable at 37 ºC73. Caveolin, a protein normally 
found in a subset of lipid rafts, is not present in tetraspanin DRMs, and no 
glycosylphosphatidylinositol (GPI)–anchored proteins, usually enriched in lipid rafts, 
have been found to associate with tetraspanins71, 74. Therefore, from the biochemical 
properties and protein content, these microdomains are novel membrane compartments 
different from lipid rafts; because of their high tetraspanin concentration, they were 
named tetraspanin-enriched microdomains. 
In another report, CD9, CD81, and CD82 were found in the insoluble light 
fractions of gradients loaded with 0.5% TX-100 lysates from T cells in a cholesterol-
dependent manner76. CD81 was also distributed in lipid raft-like microdomains upon 
coligation of the B cell receptor and its coreceptor on B cells77. The use of TX-100 to 
isolate TEMs contrasts with the previous reports, indicating the possibility of technical 
discrepancies or cell-dependent differences, and also illustrates the limitations of this 
assay. Indeed, there are several concerns over the possible artifacts that can be the result 
from lysing cells with a detergent78. How can one be sure that the results reflect the 
physiological environment? 
Thus, other methods have been applied to confirm the relevance of TEMs in vivo. 
Silvie et al. reported the method of using a monoclonal antibody (MT81w) that binds 
mouse CD81 only when it is clustered with its associated proteins 79. This antibody was 
proposed as a marker for the tetraspanin web. Binding of MT81w was decreased when 
cells were treated with ΜβCD, supporting the hypothesis that cholesterol is important in 
maintaining the tetraspanin web, probably through TEMs79. However, TEMs seemed 
mostly an abstract model until a recent report by Thali’s group allowed, for the first time, 
the visualization of TEMs80. By using fluorescence microscopy, the localization of CD9, 
CD63, CD81, and CD82 (three at a time) at the surface of HeLa cells was determined. 
Several hundred TEMs were found; half of them contained all three tetraspanins tested. 
This was further supported by electron micrographs showing CD9 and CD63 together in 
restricted microdomains80. 
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Tetraspanin functions 
What do tetraspanins do? At first glance, this seems a very challenging question 
to answer when one is presented with the variety of biological functions tetraspanins have 
been linked to, from immunology to cancer and infectious diseases. However, an in-depth 
examination reveals a common factor among these roles: tetraspanin functions deeply 
rely on their association with binding partners and their belonging to the tetraspanin web. 
Thus, depending on the proteins they interact with, tetraspanins can influence multiple 
processes. This section will present the major functions that tetraspanins are known to 
influence. However, these probably represent just the tip of the iceberg: as more 
tetraspanins are studied and more binding partners are discovered, this list is likely to 
grow extensively in the near future. 
Immunology 
CD81 and the B cell coreceptor 
The B cell coreceptor is composed of CD19, CD21, and the tetraspanin CD81. It 
plays a role in regulating the threshold of activation of the B cell receptor (BCR)81. CD21 
is a receptor for complement molecule C3d. When the BCR and the B cell coreceptor are 
both engaged by C3d-bound antigen, the threshold of activation is considerably lowered. 
As described before, CD81 interacts directly with CD19. Other tetraspanins have been 
shown to co-immunoprecipitate CD19; however, these associations only occur under 
conditions maintaining the tetraspanin web, suggesting they probably bind CD19 via 
CD8182. The specificity of the CD19/CD81 complex was further confirmed by the 
phenotype of mice lacking CD81: B cells lacking CD81 express a reduced level of CD19 
at the cell surface. Similar results were obtained by three independent groups83-85. 
Moreover, this phenotype is characteristic of CD81-null mice only; B cells of mice 
lacking CD9, CD37, or Tssc6 present normal surface levels of CD1986. 
This reduction of CD19 at the plasma membrane is thought to be due to a defect 
in its maturation, and the first transmembrane domain of CD81 is sufficient for proper 
CD19 trafficking to the surface14, 87. CD81 also has a role in stabilizing the B cell 
coreceptor and the BCR within microdomains. Upon costimulation of those complexes, 
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the BCR and B cell coreceptor distribute to lipid rafts. However, this localization is 
prevented in B cells lacking CD8177. 
T cell – antigen presenting cell interaction 
Another phenotype of CD81-null mice is a reduction in Th2 responses. Th2 
responses lead to the activation of the humoral branch of the immune system to fight 
extracellular pathogens, and are characterized by the production of specific cytokines 
such as IL-4. It is possible to artificially stimulate this type of T cell dependent signaling 
events by injecting mice with antigens combined with certain adjuvants. In this way, it 
was found that CD81-null mice were not able to produce normal amounts of antibody 
upon stimulation of Th2 responses88. These mice also lacked the ability to undergo 
airway hyperreactivity (AHR), a Th2-dependent event that is a characteristic of asthma89. 
Chimeric mice lacking CD81 only in B cells also have defects in their Th2 responses, 
suggesting that the role of CD81 in regulating Th2 responses depends on its expression in 
B cells88. However, another study pointed to the importance of CD81 in T cells in order 
to influence Th2-dependent signaling90. CD81 might play a role during the T cell – B cell 
interaction, a major event in Th2 responses. Supporting this hypothesis, CD81 has been 
found to localize within the immune synapse, a cluster of proteins facilitating the binding 
of peptide-loaded MHC class II molecules to the T cell receptor (TCR)91. CD81 is also 
known to associate with CD4 and MHC class II proteins92, 93. 
Other tetraspanins share the ability to bind antigen-presenting proteins. In 
addition to CD81, tetraspanins CD9, CD53, CD63, and CD82 associate with MHC class 
II molecules93-95. These interactions are thought to occur within microdomains. Several 
tetraspanins are present in MHC class II-enriched compartments originating in 
multivesicular bodies (discussed above, p6). Tetraspanins are also enriched in 
microdomains containing a subset of MHC class II proteins loaded with specific peptides 
and characterized by the CDw78 epitope96. Although the functional consequence of these 
associations in antigen presentation remains unclear, it is possible that tetraspanins have a 
role in the stability of these proteins within membrane microdomains. 
A common feature among mice lacking CD37, CD81, CD151, and Tssc6 is the 
hyperproliferation of T cells upon TCR stimulation, implying tetraspanins might have a 
negative regulatory effect on T cell signaling40, 85, 97, 98. However, antibodies recognizing 
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CD9, CD53, CD81, and CD82 have a costimulatory activity on T cells, also leading to an 
increase in proliferation99-101. For CD9 and CD81, this effect has been shown to be 
independent of CD28, a major player leading to costimulatory signals102, 103. These results 
seem to contradict data obtained from knockout mice. However, a model has been 
proposed to reconcile them where the tetraspanin-specific antibodies would act by 
bringing TEMs in close proximity with the immune synapse, and facilitating TCR 
signaling. On the other hand, the absence of specific tetraspanins in the knockout mice 
might cause rearrangements in the immune synapse, also leading to T cell activation104. 
This hypothesis, however, remains to be confirmed with experimental data. 
Leukocyte adhesion 
An important step in infiltration of leukocytes from the bloodstream to a site of 
infection is the attachment of circulating leukocytes to endothelial cells (leukocyte 
rolling). Cells from CD81-null mice have a defect in integrin-dependent attachment to 
VCAM-1 (an adhesion molecule required for rolling) under shear flow in an assay 
designed to mimic the force of circulating blood105. Moreover, knockdown of CD9 and 
CD151 also lowers the efficiency of attachment in a similar assay106. 
Cancer 
Correlation between tetraspanins and metastasis 
The relationship between tetraspanins and cancer goes back over 20 years when 
the first tetraspanins were isolated in cancer-related screens. Most of the attention has 
been focused on two tetraspanins: CD82 and CD9. 
In the early 1990’s, a screen was designed to identify genes able to inhibit 
metastatic potential of the rat prostate cancer cell line AT6.1. The major gene isolated in 
this screen was named KAI1, for “kang ai” meaning anticancer in Chinese107. KAI1 is 
still used today as an alternative name for CD82. AT6.1 cells transfected with CD82 were 
introduced into nude mice resulting in a decrease in the number of lung metastases 
compared with injection of control AT6.1 cells107. Numerous groups have further 
confirmed this function in the regulation of metastasis. The expression levels of CD82 in 
cancers of advanced metastatic stages was found to be reduced when compared to early 
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stages in many types of cancers: pancreatic, esophageal, prostatic, non-small cell lung, 
colorectal, hepatocellular, breast, bladder, cervical, ovarian, and endometrial cancers108-
118. In several cases, the loss of CD82 expression was related to poor prognosis111, 119. 
Moreover, when comparing CD82 expression in cell lines corresponding to various types 
of cancers vs. normal cell lines, there was an inverse correlation between CD82 levels 
and cancer progression120. Interestingly, the downregulation of CD82 seems to be 
restricted to the late, metastatic, stages of cancer: in pancreatic cancer, CD82 was actually 
upregulated during the early stages of tumor progression before being downregulated in 
advanced stages108. Moreover, mice injected with AT6.1 cells expressing CD82 did not 
show any difference in primary tumor size compared to mice injected with control AT6.1 
cells, suggesting that CD82 suppresses metastatic potential, but not early events of tumor 
progression107. The molecular mechanism causing downregulation of CD82 in cancer 
remains obscure. It probably acts at the transcriptional level since both mRNA and 
protein are affected112. No mutation has been found in the CD82 gene from cancerous 
tissues110, 117. Surprisingly, very little is known about the transcriptional regulation of 
tetraspanins, and future studies to determine the factors involved in tetraspanin gene 
expression will be useful to understand their regulation in cancer. 
Similarly, CD9 expression is inversely correlated with cancer malignancy in 
multiple tissues: skin (melanoma), breast, lung, colon, pancreas, and esophagus109, 119, 121-
125. Another tetraspanin, CD63, was discovered as the antigen recognized by an 
antimelanoma antibody, and its expression is also inhibited in advanced stages of 
melanomas126. However, less is known about the differential expression of CD63 in other 
cancers, even though it is ubiquitously expressed throughout the human body. The effect 
of CD63 may be limited to melanoma. In vitro studies have supported the histological 
evidence by showing that overexpression of CD9 and CD82 in metastatic cell lines is 
able to inhibit cell motility127-131. 
The involvement of other tetraspanins in cancer development is less clear. 
CD151, in contrast with CD9 and CD82, functions as a positive regulator of metastasis. 
In non-small cell lung cancer, high CD151 expression levels are correlated with a poor 
prognosis132. Overexpression of CD151 in HeLa cells stimulates motility, and cells from 
CD151-null mice have impaired migration 97, 133, 134. The evidence concerning CD81 is 
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inconclusive: on one hand, CD81 is expressed at higher levels in squamous cell 
carcinoma relative to normal tissues, but on the other hand, metastatic potential is 
correlated with low CD81 expression in hepatocellular carcinoma135-137. 
Possible molecular mechanisms 
Even though the correlation between tetraspanins and malignancy has been 
known for a while, the molecular mechanism behind it remains unclear. However, several 
models have been proposed. The main one involves the well-documented association 
between tetraspanins and integrins (discussed above, p10). Since integrins are major 
players in binding and responding to the extracellular matrix, it seems logical that 
tetraspanins would regulate cell motility in an integrin-dependent manner. With this 
hypothesis in mind, Zhang et al. examined the activation state of molecular components 
downstream of integrins in a prostate metastatic cell line stably expressing CD82127. 
These cells have reduced motility compared to cells lacking CD82. Protein p130CAS was 
found to be downregulated in the presence of CD82, and p130CAS overexpression in 
CD82-expressing cells stimulated their motility to a similar level as cells without 
CD82127. Thus, p130CAS, a protein downstream of integrin signaling, appears to be 
important for CD82-dependent motility. In another report, the same group found that a 
CD151 mutant protein that is not internalized as efficiently as the wild-type protein is 
unable to stimulate integrin-dependent migration18. The authors proposed that the 
regulation of integrin endocytosis by CD151 leads to an increase in migration. 
Another model to explain how tetraspanins regulate motility is through growth 
factor receptors. CD82 associates with EGFR and overexpression of CD82 reduces EGF-
induced cell motility130. CD82 has a negative impact on the dimerization of EGFR and 
activation of downstream signaling upon EGF stimulation130, 138. 
The integrin and growth factor receptor hypotheses are not mutually exclusive as 
illustrated by recent work from Miranti’s group, who reported that CD82 expression 
suppresses integrin-mediated cell migration and invasion of metastatic prostate cells129. 
Importantly, integrin-based activation of c-Met, the receptor for hepatocyte growth 
factor/scatter factor (HGF/SF), was also reduced in these cells upon CD82 expression129. 
Activation of Src and downstream molecules, including p130CAS, was also inhibited by 
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CD82129. Therefore, the authors suggested that CD82 regulates integrin-mediated 
migration through the growth factor receptor c-Met. 
CD82 and DARC 
Recently, an exciting new mechanism has been proposed to explain the role of 
CD82 as a metastasis suppressor gene. In an attempt to identify novel CD82-binding 
proteins, the chemokine receptor DARC (Duffy antigen receptor for cytokines) was 
isolated by yeast two-hybrid139. CD82 on the surface of cancer cells that have entered the 
bloodstream is thought to associate with DARC proteins expressed at the cell surface of 
endothelial cells139. This interaction results in senescence and inhibition of proliferation 
of the cancer cells139. Strikingly, the number of lung metastases caused by the injection of 
CD82-expressing cells into mice was greatly increased in a DARC-null background, 
supporting the essential role of DARC in CD82-mediated metastasis139. This is a rare 
example of a trans interaction (i.e., the proteins are found opposite to each other in two 
separate cells) between a tetraspanin and another protein, and these results open the field 
to new possibilities and indicate that more than one mechanism are likely to be involved 
in the regulation of metastasis progression by tetraspanins. 
Infectious diseases 
CD81 and hepatitis C virus 
During the past decade, CD81 has captured the attention of virologists because of 
its role in hepatitis C virus (HCV) infectivity. HCV is an RNA virus from the family 
Flaviviridae that can cause liver cirrhosis and subsequent hepatocellular carcinoma. The 
viral glycoprotein E2 is essential for virus binding and entry into hepatocytes. CD81 was 
isolated in a screen designed to identify E2-binding proteins140. The LEL of CD81 was 
found to mediate this interaction140. This association is specific to human CD81 (hCD81) 
as other tetraspanins (CD9, CD63, and CD151) and the African green monkey CD81 
(AgmCD81) homolog are not able to bind a recombinant version of E2141. AgmCD81 has 
only four different amino acids in the LEL relative to hCD81; therefore, the lack of E2 
binding to AgmCD81 was particularly useful in mapping the LEL region important for 
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E2 association. Phenylalanine 186, a residue located within the head subdomain of CD81 
LEL, was shown to be critical for binding4. 
The in vivo relevance of this protein interaction was not clear until CD81 was 
confirmed to be required for HCV cell entry. For a long time, a major obstacle in HCV 
research has been the lack of a cell culture system. However, recently, two novel tools 
were made available to overcome this problem: 1) HCV pseudoparticles (HCVpp) 
consisting of HIV pseudoparticles and E1 and E2 glycoproteins from HCV, and 2) a 
particular HCV strain that is able to replicate in cell culture (HCVcc)8, 142. CD81-specific 
antibodies or downregulation of CD81 by RNA interference inhibit HCVpp infection of 
permissive cells8. Similarly, HCVcc infectivity was dependent on CD81142. Moreover, in 
a more physiologically relevant assay, Molina et al. demonstrated the importance of 
CD81 in the infection of primary hepatocytes using serum isolated from patients infected 
with HCV143. 
However, although CD81 is necessary for HCV infection, several pieces of 
evidence indicate that CD81 is not sufficient to confer permissivity to HCV. First, CD81 
has a wide distribution throughout the human body, whereas HCV infection is 
predominantly restricted to the liver. Second, the CD81 homolog in tamarins is able to 
bind E2 even though this species is refractory to HCV infection144. Third, Shaw et al. 
found that CD81 could not associate with E2 proteins from a specific HCV genotype145. 
Fourth, transgenic mice expressing the human form of CD81 are not infected by HCV. 
And fifth, other proteins have been identified to associate with E2, including scavenger 
receptor class B type 1 (SR-B1), DC-SIGN and L-SIGN, low-density lipoprotein 
receptor, and claudin 1 (CLDN1)146-149. Using an HCVpp cell entry assay, both CD81 and 
SR-B1 were found to be required for entry150. However, expression of these two proteins 
was not enough to allow HCV entry into non-hepatic non-permissive cells150. Thus, it 
was suggested that additional proteins present in liver cells might be involved in HCV 
cell entry. Recently, CLDN1, a protein distributed within tight junctions and enriched in 
liver cells, was found to play a role in HCV entry149. Among all the proteins found to 
mediate HCV entry, CLDN1 is the only one that is known to allow HCV entry into non-
hepatic non-permissive cells149. A subsequent report showed the association between 
CLDN1 and CD81 by using FRET analysis151. However, even the presence of CLDN1, 
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CD81, and SR-B1 is not sufficient in some cell lines to mediate HCV entry149. Therefore, 
infection of hepatocytes by HCV is likely to be a highly complex mechanism involving 
multiple factors. Interestingly, EWI-2wint, a cleavage product of EWI-2 not present in 
hepatocytes, was reported to inhibit HCV entry by preventing the association of CD81 
and E2152. 
Other tetraspanin-virus functional associations 
A role for tetraspanins in viral infection is not unique to CD81. CD82 has a 
negative effect on the cell-cell fusion event occurring during infection by human T-cell 
lymphotropic virus type 1 (HTLV-1)153. A monoclonal antibody against CD63 (but not 
CD9, CD81, and CD82) can inhibit CCR5-dependent infection of macrophages by 
human immunodeficiency virus (HIV)154. Also, HIV-1 Env and Gag proteins are 
distributed in TEMs at the cell surface, together with cellular proteins required for virus 
budding80. A CD9-specific antibody blocks feline immunodeficiency virus (FIV) 
infectivity155. However, unlike the function of CD81 in HCV, this inhibition is not 
specific for cell entry155. CD9 has also been linked to the infectivity of canine distemper 
virus (CDV)156. Finally, a new tetraspanin was recently isolated from the mosquito Aedes 
albopictus because of its higher expression levels after Dengue 2 virus infection37. 
CD81 and Plasmodium sporozoites 
The malaria-causing parasite (Plasmodium spp.) undergoes a complex life cycle 
involving multiple stages. One of these stages, the infection of liver cells by sporozoites, 
is thought to be dependent on CD81. Plasmodium yoelii (a rodent parasite) is not able to 
infect mice lacking CD81157. Mice lacking CD9 were unaffected, implying a specific role 
for CD81. Moreover, a monoclonal antibody recognizing CD81 is able to block infection 
of hepatocytes by the human parasite Plasmodium falciparum157. No Plasmodium-
specific protein has been found to interact with CD81, suggesting that CD81 does not act 
as a receptor in this case (in contrast with its role in HCV infection)157. The antibody 
MT81w, which binds to CD81 only when associated with other proteins within the 
tetraspanin web, can also inhibit Plasmodium infectivity79. Moreover, infection of 
hepatocytes is cholesterol-dependent, supporting a role for membrane microdomains in 
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infectivity79. Thus, it has been proposed that TEMs are important for Plasmodium 
infection. 
 
Additional potential tetraspanin roles in pathogenicity of microorganisms include 
the mediation of PLS1 in host plant invasion by fungi, and the characterization of 
uroplakin Ia as a receptor for Escherichia coli strains causing urinary tract infection34, 158. 
Others 
CD9 is known for its role in fertility: only about half of female CD9-null mice are 
able to reproduce as compared to wild-type littermates159. This is caused by a defect in 
sperm-egg fusion159. However, the molecular mechanism remains unknown. 
Several tetraspanins play roles in neurobiology. Drosophila Late bloomer is 
important for neuromuscular junction formation27. CD9 may play a role in the formation 
of paranodes (structures found at the axoglial junctions of myelinated axons)160. The 
integrity of rod photoreceptor disc rims is thought to rely on the expression of peripherin-
2 and ROM-154. Drosophila Sunglasses mediates internalization of rhodopsin upon light 
activation28. And CD81 has recently been found to play a role in phagocytosis of 
photoreceptor outer segments by retinal pigment epithelial cells161. 
Tetraspanin uroplakins are essential for the maintenance of bladder structure and 
function as a permeability barrier61. 
Regulation of the tetraspanin web 
Glycosylation 
Even though most tetraspanins are thought to be glycosylated, only a few reports 
have focused on the effect of glycosylation on tetraspanin function (surprisingly, at the 
time this review was written, only 13 hits result from a PubMed search using “tetraspanin 
glycosylation” as key words). Mutation of all three N-glycosylation sites of CD82 
enhances its binding to integrin α5, and CD82 glycosylation is thought to be important for 
its role in cell motility162, 163. Interestingly, the level of CD82 glycosylation seems to be 
variable when comparing various cancer cell lines120. During the maturation of dendritic 
cells, CD63 is modified by the addition of polylactosaminoglycans164. Dendritic cell 
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maturation is characterized by the distribution of MHC class II complexes from 
intracellular vesicles to the cell surface for antigen presentation. Because of the reported 
association of CD63 with MHC class II proteins in MHC class II-enriched intracellular 
compartments (discussed above, p6 and 14), the change in CD63 glycosylation was 
proposed to play a role in this maturation event164. Uroplakin tetraspanins UP Ia and UP 
Ib are both glycosylated. Nevertheless, despite a high sequence identity (about 40%), 
there is a major difference in the sugar molecules they carry165. Whereas UP Ia is 
modified with high mannose glycans, UP Ib carries a complex type of glycosylation. This 
difference has functional consequences since only UP Ia is a receptor for uropathogenic 
E. coli FimH, a protein that preferentially recognizes terminal mannose molecules165. The 
mechanism behind the differential glycosylation between uroplakin tetraspanins remains 
unknown. Additionally, mutation of glycosylation sites in UP Ib did not prevent its 
trafficking to the cell surface12. 
Palmitoylation 
Even though acylation of CD9 and CD81 was known for almost 20 years, the role 
of palmitoylation in the regulation of tetraspanins was practically unknown until a report 
by Rubinstein’s group in 2002166-168. Palmitoylation is a reversible post-translational 
modifications resulting in attachment of palmitic acid to intracellular cysteine residues169. 
The palmitoylation of CD9, CD37, CD53, CD63, CD81, CD82, CD151, and A15 have 
been reported168, 170.  
Membrane microdomains 
The palmitoylation state of several proteins has been associated with their 
localization within membrane compartments such as lipid rafts169. Does this property 
apply to tetraspanins? As discussed previously, CD81 is required for the stabilization of 
the B cell coreceptor and the BCR in lipid rafts upon coligation. Cherukuri and 
colleagues showed that palmitoylation of CD81 is important for this function171. First, 
CD81 palmitoylation levels increase when both the BCR and its coreceptor are 
stimulated. This inducible palmitoylation is dependent on the presence of lipid rafts. 
Second, when an inhibitor of palmitoylation (2-bromopalmitate or 2-BP) is added to the 
cells, the BCR and coreceptor do not partition into lipid rafts. Thus, the authors proposed 
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that the coligation of both receptor complexes leads to their distribution into 
microdomains, and subsequent activation of downstream signaling, via CD81 
palmitoylation171. It is interesting to note that CD81 is constitutively palmitoylated in the 
absence of stimuli. Moreover, treatment with 2-BP was unable to inhibit this basal level, 
suggesting differences between the mechanisms controlling inducible vs. constitutive 
palmitoylation of CD81171. These results also imply that the partitioning of CD81 into 
lipid rafts is not mediated by palmitoylation in an all-or-none fashion. Indeed, basal 
levels of CD81 palmitoylation are not sufficient to trigger this change. This process 
seems to be more subtly regulated by the level of palmitoylation. At this point, it is not 
clear whether the increase in CD81 palmitoylation reflects an increase in number of 
palmitoylated proteins or in the number of palmitate molecules per CD81 protein. 
Research on palmitoylation of other tetraspanins has focused on constitutive 
palmitoylation levels. By mutating juxtamembrane cysteines—potential palmitoylation 
sites—palmitoylation-deficient mutant versions of CD9 and CD151 were generated168, 170, 
172. One of the major questions addressed concerned their distribution within TEMs as 
analyzed by flotation in sucrose gradients. For both tetraspanins, palmitoylation-deficient 
proteins were found in DRMs in amounts comparable to their wild-type counterparts168, 
170, 172. A similar result was obtained when cells were treated with 2-BP172. 
Subcellular distribution 
Another common property of palmitoylation in other membrane proteins is the 
ability to influence their trafficking to the plasma membrane169. In the case of CD82, a 
similar effect was found. When a palmitoylation-deficient CD82 construct was stably 
expressed in prostate cancer cells, its detection by flow cytometry was reduced to about 
half the level of wild-type CD82173. This was explained by an increased presence of the 
mutant proteins in intracellular vesicles (endosomes and lysosomes). The intracellular 
distribution of a palmitoylation-deficient CD151 was also found to be altered in a report 
from Hemler’s group; in this case, the mutant proteins have lost the ability to traffic to 
endosomal and lysosomal vesicles170. However, the surface expression of CD151 remains 
unchanged in the absence of palmitoylation. These results contrast with another study by 
Berditchevski et al. where they found no difference in intracellular localization of their 
mutant CD151172. The authors indicated that this might be due to the differences between 
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the constructs used. The first report mutated four cysteines in order to prevent 
palmitoylation, whereas Berditchevski et al. showed that six cysteines needed to be 
replaced in order to efficiently inhibit palmitoylation170, 172. Another possible problem is 
the presence of a GFP tag in the former CD151 construct170. 
A palmitoylation-deficient CD9 construct showed no difference in surface 
expression compared to the wild-type protein168. On the other hand, surface detection of a 
CD81 construct lacking six cysteines is markedly reduced relative to wild-type79. 
Therefore, the effect of palmitoylation on subcellular localization might depend on the 
tetraspanin studied. However, it is too early to rule out discrepancies in the methodology 
used. Future work applying additional methods to inhibit palmitoylation of various 
tetraspanins will be helpful in resolving this question. 
Protein associations 
A major consensus among studies using palmitoylation-deficient proteins of CD9, 
CD82, and CD151 is the importance of palmitoylation in tetraspanin-tetraspanin 
interactions—a key component in assembling the tetraspanin web. Yang et al. showed a 
decrease in the association between mutant CD151 and tetraspanins CD9 and CD63170. 
The CD151 mutant construct reported by Berditchevski et al. is unable to efficiently 
immunoprecipitate CD63 and CD81172. Similarly, palmitoylation-deficient CD82 has a 
weakened interaction with CD9 and CD81 compared to wild-type CD82173. Work on a 
CD9 mutant protein by Rubinstein’s group adds a level of complexity168. The authors 
make the distinction between two types of tetraspanin-tetraspanin interactions. Their 
detection depends on the presence of divalent cations (Ca2+ and Mg2+) or EDTA in the 
lysis buffer. Only highly stable associations between tetraspanins are thought to remain in 
the presence of EDTA. Interestingly, the effect of CD9 palmitoylation appears to be 
restricted to the EDTA-insensitive CD9 associations with CD53 and CD81; associations 
detected in the presence of divalent cations are not dependent on the palmitoylation state 
of CD9168. It should be noted that the results described above on the associations of 
palmitoylation-deficient CD82 and CD151 with other tetraspanins were obtained in lysis 
buffers lacking EDTA. The functional relevance of a possible role of divalent cations in 
tetraspanin interactions remains unknown. 
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Whereas palmitoylation is important for tetraspanin-tetraspanin associations, it 
does not seem to facilitate the primary interactions between tetraspanins and their specific 
binding partners. Indeed, mutation of juxtamembrane cysteines in CD9 does not impair 
binding to CD9P-1 (EWI-F)168. Similarly, mutant CD151 associates with integrin α3β1 as 
efficiently as wild-type CD151170. 
Homodimerization of tetraspanins is also thought to be palmitoylation 
independent. Formation of CD9 dimers, as shown by chemical cross-linking, remains 
unaltered when its putative palmitoylation sites are mutated62. However, a subsequent 
report found that the further clustering of CD9 homodimers (homoclustering) is 
dependent on palmitoylation174. This result was obtained by using a monoclonal antibody 
that recognizes CD9 only when it is clustered. Binding of this antibody to cells 
expressing a palmitoylation-deficient CD9 is reduced compared to wild-type. 
Palmitoylation was proposed to facilitate the switch between heteroclustering and 
homoclustering. When CD9 is palmitoylated, it tends to cluster with itself and exclude 
other proteins. In this way, a palmitoylation-deficient CD9 is able to bind EWI-2 more 
efficiently compared to wild-type174. 
As an alternative approach to study the effect of palmitoylation in protein 
interactions, 2-BP was used. However, in contrast with the previous results, 2-BP does 
not have a significant effect on the association between CD9 and CD151172. The authors 
proposed that palmitoylation plays a role only in the early stages when tetraspanins first 
form interactions with other tetraspanins while they traffic to the plasma membrane. 
Once those associations are established, palmitoylation is no longer required and other 
types of binding come into place to maintain the tetraspanin web. This would explain 
why the addition of 2-BP has no effect since these interactions would be already in place 
before the treatment. Future studies will be needed to confirm this result. 
Functional relevance 
Expression of the palmitoylation-deficient tetraspanins described above has 
resulted in the alteration of several cellular functions. CD82 has been shown to inhibit 
cell motility (discussed above, p15) and absence of palmitoylation prevents CD82 from 
inhibiting the motility and invasion of prostate cancer cells173. Mutant CD151 protein 
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expression leads to changes in cell morphology in one report, and to an increase in the 
number of focal adhesions and in PI-3 kinase signaling in another report170, 172. 
A palmitoylation-deficient CD81 lacking six cysteines, however, does not have a 
significant effect on the infection of Plasmodium yoelii in hepatocytes79. Also, 
distribution of CD9 into exosomes is not dependent on its palmitoylation state175. 
Therefore, it is possible that not all tetraspanin functions depend on palmitoylation-
dependent associations with other tetraspanins within the tetraspanin web. 
Enzymatic palmitoylation of tetraspanins 
Recent work from Hemler’s group identified a palmitoyl acyl transferase that is 
responsible for the palmitoylation of CD9 and CD151: DHHC2176. DHHC2 is part of a 
group of enzymes named after the conserved DHHC motif required for their function. 
When DHHC2, and not other DHHCs, is overexpressed, it leads to an increase in the 
palmitoylation levels of CD9 and CD151. This function seems to be specific to 
tetraspanins, as other proteins tested were not affected by the expression of DHHC2. 
Supporting the role of palmitoylation in building the tetraspanin web, DHHC2 expression 
results in an increase in CD9/CD151 association. As expected, the primary interaction 
between CD151 and α3β1 remains unaffected176. 
Surprisingly, downregulation of DHHC2 protein levels by RNA interference 
results in a decrease of CD9 and CD151 protein expression176. This is thought to be 
mediated by an increase in lysosomal degradation. Thus, degradation of tetraspanins 
might be dependent on palmitoylation. However, protein levels of palmitoylation-
deficient tetraspanins remain unchanged relative to wild-type proteins. The authors 
suggest that this discrepancy might be due to unknown side effects caused by the 
mutation of cysteines in these constructs aside from inhibiting palmitoylation176. 
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Figure 1.3 Summary of results obtained from palmitoylation-deficient tetraspanins 
 
 
The following chapters examine these post-translational modifications in two 
tetraspanins. Chapter two is centered on the characterization of palmitoylation-deficient 
CD81. A previous report used a CD81 construct lacking five cytoplasmic cysteines to 
prevent palmitoylation22. However, the predicted three-dimensional structure of CD81 
identified an additional cysteine (position 80) as a possible palmitoylation site1. Is the 
mutation of five cysteines enough to efficiently inhibit palmitoylation of CD81? In 
addition, a thorough characterization of palmitoylation-deficient CD81 has not been 
reported. Does the palmitoylation-deficient CD81 have similar properties compared to 
palmitoylation-deficient CD9, CD82, and CD151 proteins? These questions were 
addressed by generating CD81 constructs with mutations in five, six, seven, or eight 
juxtamembrane cysteines and analyzing their palmitoylation level, cellular expression, 
and association with other proteins. Chapter three is focused on Tspan-2 and its N-
glycosylation. Among the 33 human tetraspanins, the functions of more than half of 
them, including Tspan-2, remain obscure. To gain a full understanding of the tetraspanin 
web, more attention needs to be given to these tetraspanins. Similarly, little is known 
about the role of glycosylation in the tetraspanin web. We provide the first steps for a full 
characterization of Tspan-2 by investigating its expression, glycosylation, and association 
with CD81. In this way, we hope to encourage future studies on Tspan-2 and other lesser-
known tetraspanins. 
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CHAPTER 2 - Mutation of Juxtamembrane Cysteines in the 
Tetraspanin CD81 Affects Palmitoylation and Alters 
Interaction with Other Proteins at the Cell Surface 
Summary 
Palmitoylation of tetraspanins affects protein-protein interactions, suggesting a 
key role in the assembly of the tetraspanin web. Since palmitoylation occurs on 
intracellular cysteine residues, we examined whether mutating these residues in the 
human tetraspanin CD81 would affect the association of CD81 with other surface 
membrane proteins. Mutation of at least six of the eight juxtamembrane cysteines was 
required to completely eliminate detectable CD81 palmitoylation, indicating that several 
sites can be palmitoylated. Interestingly, these cysteine mutations resulted in reduced cell 
surface detection compared to wild-type CD81 as indicated by flow cytometry analysis. 
This was not due to a defect in protein trafficking, differences in protein stability, or 
reduced anti-CD81 antibody binding affinity. In contrast, total CD81 levels, as measured 
by immunoblotting, appeared to be increased with the mutant proteins. However, we 
observed that both endogenously and exogenously expressed CD81 underwent a novel 
processing event either in Golgi or at the cell surface, which was decreased in the mutant 
CD81 proteins compared to wild-type. This reduction in processing of full length CD81 
explained the apparent increase in total CD81 levels for the mutant proteins. Finally, 
CD81 associations with CD9 and EWI-2 were also impaired with the mutant proteins. 
Taken together, these findings indicate that mutation of juxtamembrane cysteines alters 
the interaction of CD81 with other proteins, thereby affecting the detection of CD81 on 
the cell surface by antibodies and accessibility by proteases.* 
                                                
* A modified form of this chapter has been accepted for publication in 
Experimental Cell Research (Delandre, C., Penabaz, T.R., Passarelli, A.L., Chapes, S.K., 
and R.J. Clem. 2009. Mutation of juxtamembrane cysteines in the tetraspanin CD81 
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affects palmitoylation and alters interaction with other proteins at the cell surface. Exp. 
Cell Res. In press.). The publisher, Elsevier, allows authors the right to include the 
journal article, in full or in part, in a thesis or dissertation. 
 30 
 
Introduction 
CD81 is a ubiquitously expressed member of the tetraspanin superfamily of 
proteins. Tetraspanins are defined by four transmembrane domains and by the presence 
of conserved cysteines in addition to a CCG motif in the large extracellular loop. Their 
most striking property is the ability to interact with multiple proteins (e.g., receptors, 
adhesion proteins, Ig superfamily members, and signaling molecules, as well as other 
tetraspanins). These associations are thought to occur mainly in membrane compartments 
such as lipid rafts and tetraspanin-enriched microdomains (TEMs), thereby forming a 
membrane network known as the “tetraspanin web”. Since they regulate the function of 
their binding partners, tetraspanins play roles in diverse cellular processes including 
adhesion, proliferation, fusion, and signaling86, 177. However, redundancy among the 
members of the superfamily and the multiplicity of associations make the understanding 
of their specific molecular mechanism a challenging task. 
Research on CD81 has largely focused on its regulatory role in the immune 
system since its discovery in 1990 as a target of an antiproliferative antibody on 
lymphoma B cells86, 178. Through its direct association with CD19, CD81 participates in 
the B cell coreceptor, a complex of integral membrane proteins (CD19/CD21/CD81) that 
lowers the threshold of activation of the B cell receptor (BCR) in response to opsonized 
antigens68, 81. CD81 is thought to facilitate trafficking of CD19 and stabilize the B cell 
coreceptor14, 77. Accordingly, B cells from CD81-null mice express less CD19 on the cell 
surface and present a weaker antibody response to Th2-inducing antigens83-85, 88. Lack of 
CD81 also results in a defect in allergen-induced airway hyperreactivity, a Th2-
dependent reaction commonly found in asthma patients89. T-cell function is also 
influenced by CD81 since T cells isolated from CD81-deficient mice proliferate more 
rapidly after T-cell receptor cross-linking in comparison with wild-type littermates85. 
Moreover, CD81 interacts with CD4 and CD8, and is able to induce a T-cell 
costimulatory signal92, 102, 179. CD81 has also been found to dynamically concentrate in 
the immune synapse, a cluster of proteins formed during the close contact between T 
cells and antigen-presenting cells essential for T-cell activation91. Thus, all these 
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immunological CD81 functions depend on interactions and clustering with other proteins, 
but how CD81 is able to regulate these associations remains unclear. 
It is possible that protein modifications have a role in these functions. 
Palmitoylation is a post-translational process that attaches palmitic acid to proteins via 
thioester linkages to cysteine residues. Since it is a reversible process, it can be 
considered an “on-off” switch similar to protein phosphorylation. Addition of fatty acids 
is thought to provide proteins more hydrophobic stability in cellular membranes, thus 
influencing their fate during trafficking and partitioning into membrane microdomains169, 
180. Most tetraspanins possess cysteines in their intracellular domains that may be 
available for palmitoylation, and all tetraspanins tested so far have been shown to be 
acylated22, 168, 170, 172, 173. Palmitoylation-deficient constructs have been generated for 
several tetraspanins (CD9, CD81, CD82, and CD151), revealing a role for palmitoylation 
in protein association, cell motility, morphology, adhesion-dependent signaling, and 
oxidative stress22, 170, 172, 173. In B cells, coligation of the BCR with the CD19/CD21/CD81 
complex induces CD81 palmitoylation, a necessary event resulting in the localization of 
this cluster of proteins into lipid rafts and signaling171. In contrast, palmitoylation of CD9 
and CD151 does not seem to be required for their association with TEMs168, 170, 172. 
In this study, we examined whether mutation of intracellular cysteine residues that 
are sites of palmitoylation would affect CD81 trafficking and/or interactions with other 
proteins. To address this issue, we characterized CD81 mutant proteins with substitutions 
in five, six, seven, or eight cysteines in the cytoplasmic and transmembrane domains. In 
particular, we assessed CD81 expression at the plasma membrane, palmitoylation levels, 
association with direct binding partners, and protein stability. Our results highlight the 
importance of intracellular and transmembrane cysteines for the proper expression and 
post-translational modification of CD81 and its interaction with other proteins. 
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Experimental Procedures 
Cell lines, antibodies, and plasmids 
Baby Hamster Kidney (BHK-21) cells were generously provided by Carol Blair 
from Colorado State University. African green monkey COS-7, human embryonic kidney 
293, and human fibrosarcoma HT1080 cells were obtained from Scott C. Todd (Kansas 
State University). Cell lines were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% heat-inactivated fetal bovine serum (FBS). Anti-CD81 
monoclonal antibody (5A6) was obtained from Scott C. Todd and its specificity for CD81 
has been described previously178. Anti-hEWI-2 monoclonal antibody (8A12) was a 
generous gift from Eric Rubinstein (INSERM U268, France). Anti-V5-HRP antibody was 
obtained from Invitrogen (Carlsbad, CA), and anti-hCD9 monoclonal antibody (M-L13) 
was purchased from BD Biosciences (San Jose, CA). Human V5-tagged CD9 and EWI-2 
constructs were generated by cloning the corresponding cDNAs into pcDNATM3.1/V5-
His TOPO® vector (Invitrogen). 
Site-directed mutagenesis and transfection 
The human CD81 (CD81-5C) mutant with mutations in the cysteines at positions 
6, 9, 89, 227, and 228 in the intracellular domains has been described previously22. This 
earlier report, however, mistakenly labeled the residue in position 89 as being an alanine 
instead of a serine. The construct CD81-6C was obtained by mutating cysteine 80 to a 
serine residue using CD81-5C as a template and the QuikChange® Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). Similarly, cysteine 97 was replaced by a 
serine using CD81-6C as a template to obtain the construct CD81-7C. Finally, cysteine 
104 was changed to a serine using CD81-7C as template to generate CD81-8C. 
Constructs CD81-5CA, -6CA, -7CA, and -8CA were generated using the same sequential 
scheme but replacing cysteines to alanines instead of serines. The constructs were 
sequenced to verify the substitutions and to assure other nonspecific mutations did not 
occur. 
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BHK, COS-7, 293, and HT1080 cells were transfected with different plasmids as 
indicated using LipofectamineTM 2000 (Invitrogen) according to the directions of the 
manufacturer. 
Flow cytometry 
Transfected cells were harvested with 0.02% EDTA and stained with αCD81 
antibody 5A6, αCD9, or αEWI-2 antibodies (1 µg/106 cells) for 20-30 min on ice. Cells 
were washed with phosphate-buffered saline (PBS) before incubation with Alexa Fluor® 
488 goat anti-mouse IgG (BD Biosciences) (1 µg/106 cells) for 20 min on ice. Samples 
were analyzed with a BD FACSCaliburTM flow cytometer (BD Biosciences) and 
WinMDI 2.9 software (The Scripps Research Institute). 
Metabolic labeling 
To assess palmitic acid incorporation, COS-7 cells were plated on 100-mm dishes 
and transfected with a control vector expressing GFP or with vectors expressing wild-
type or mutant CD81. At two days post-transfection, cells were serum starved for 3 hours 
and labeled overnight with 300 µCi/ml palmitic acid [9,10-3H(N)] (PerkinElmer Life and 
Analytical Sciences, Wellesley, MA) in serum-free medium supplemented with 5% 
delipidated Bovine Serum Albumin (Sigma-Aldrich, St. Louis, MO). The cells were 
harvested and washed three times with PBS followed by immunoprecipitation with 
αCD81 antibody 5A6 as described below. The samples were separated by non-reducing 
SDS-PAGE, transferred to PVDF membranes, and membranes were exposed to Kodak 
BioMax MS Film (Eastman Kodak Company, Rochester, NY) for one week at -80 ºC. 
To assess protein stability, cells were biosynthetically labeled with [35S]-
methionine/cysteine. BHK cells were transfected with vectors expressing wtCD81, 
CD81-6C, or CD81-8C. The next day, transfected cells were starved in DMEM Met/Cys-
free medium (Mediatech, Inc., Herndon, VA) containing 5% dialyzed FBS (Pulse-
labeling medium) for one hour.  TRAN35S Label (MP Biomedicals, Solon, OH) was then 
added to the cells at 0.25 mCi/ml in pulse-labeling medium for one hour. After removing 
the medium containing [35S]-methionine/cysteine, cells were incubated with pulse-
labeling medium supplemented with 2 mM L-methionine and 2 mM L-cystine to start the 
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chase. Cells were harvested at the indicated time points, lysed in lysis buffer (150 mM 
NaCl, 20 mM Tris pH 7.5, 5 mM MgCl2, 10 units/ml aprotinin, 1mM PMSF, and 1 µg/ml 
pepstatin A) containing 1% Triton-X 100 (Sigma-Aldrich), and CD81 was 
immunoprecipitated with αCD81 antibody as described below. After separation by SDS-
PAGE, gels were incubated in destain solution (10% acetic acid, 30% methanol) 
overnight, soaked twice in DMSO, and treated with 22.5% fluor 2,5-diphenyloxazole 
(Acros Organics, Morris Plains, NJ) to enhance the signal. Following several washes in 
water, gels were dried and exposed to X-ray film for 2-24 hours at -80 ºC. 
Immunoprecipitation 
Cells were detached with 0.02% EDTA and lysed for one hour at 4 ºC in lysis 
buffer containing 1% Brij-99 (Sigma-Aldrich). The insoluble material was removed by 
centrifugation at 21,000g for 15 min at 4 ºC. The antibody (5A6) was captured on Protein 
G-Sepharose® beads (Sigma-Aldrich) for one hour. After washing off the excess 
antibody, the lysates were added to the antibody-bead mixture and left rotating overnight 
at 4 ºC. Suspensions were centrifuged at 2,300g for 5 min at 4 ºC, the supernatants were 
collected, and the pellets were washed twice with lysis buffer containing 1% Brij-99, 
separated by SDS-PAGE under non-reducing conditions, and transferred to an 
Immobilon-P membrane (Millipore, Billerica, MA). 
Immunoblotting 
Proteins immobilized on PVDF membranes were blocked for one hour at 4 ºC in 
Tris-buffered saline with 0.1% Tween-20 (TBS-T) containing 5% non-fat milk. To detect 
CD81, a solution of αCD81 antibody 5A6 was diluted 1:10,000 in TBS-T containing 1% 
non-fat milk and was incubated with the membrane for one hour at room temperature. 
After washing, ImmunoPure® antibody goat anti-mouse HRP (diluted 1:20,000) (Pierce 
Biotechnology, Rockford, IL) was used as the secondary antibody for 30 min at room 
temperature. For V5 detection, anti-V5-HRP antibody was used at 1:5,000 for 90 min at 
room temperature. All blots were visualized by applying SuperSignal® West Pico 
Chemiluminescent Substrate (Pierce Biotechnology) and exposing to X-ray film. 
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Surface biotinylation labeling 
Cells were detached with 0.02% EDTA, washed three times with PBS (pH 8), and 
incubated with EZ-Link Sulfo-NHS-LC-Biotin (Pierce Biotechnology) or PBS alone for 
30 min at 4 ºC.  Biotin was dissolved in PBS (pH 8) just before use. Following 
incubation, cells were washed three times with PBS (pH 7.2) containing 100 mM glycine 
to remove unbound biotin. Cells were lysed for one hour at 4 ºC in lysis buffer containing 
1% Triton X-100, insoluble material was removed by centrifugation at 21,000g for 15 
min at 4 ºC, and biotinylated proteins were pulled down with Streptavidin-Agarose beads 
(Sigma-Aldrich) overnight at 4 ºC. Samples were analyzed by immunoblotting as 
described above. 
Saturation binding assay 
BHK cells transfected with a control vector, or with vectors expressing wtCD81 
or CD81-8C, were harvested with 0.02% EDTA, and incubated with increasing 
concentrations of αCD81 antibody 5A6-FITC (34, 67, 201, 402, 670, and 1072 nM) 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for one hour on ice. Samples were 
analyzed with a BD FACSCaliburTM flow cytometer (BD Biosciences). Saturation 
isotherm curves and KD values were obtained using GraphPad Prism 4 (GraphPad 
Software, Inc., San Diego, CA) and the following equation: Y=(Bmax.X)/(KD+X), where 
X is the antibody concentration and Y is the mean fluorescence intensity value. Mean 
Fluorescence Intensity (MFI) values from control vector samples (nonspecific binding) 
were subtracted from MFI values from wtCD81 and CD81-8C samples to obtain specific 
binding values. To confirm that the antibody concentrations were saturating under these 
conditions, supernatants were collected after antibody incubation to measure fluorescence 
from unbound 5A6-FITC molecules and compared to fluorescence from total number of 
5A6-FITC molecules added to the cells using a VICTOR3 plate reader (PerkinElmer Life 
and Analytical Sciences). No difference in binding among samples was observed when 
an isotype control (normal mouse IgG1-FITC, Santa Cruz Biotechnology, Inc.) was used 
(data not shown). 
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Brefeldin A treatment 
The medium was removed from cells at one day post-transfection and replaced 
with fresh medium containing absolute ethanol (vehicle control wells) or brefeldin A 
(Sigma-Aldrich) at 10 µg/ml for 10 hours in the 37 ºC incubator. Cells were then 
detached and assayed for CD81 expression by flow cytometry or immunoblotting as 
described above. 
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Results 
Expression of CD81 palmitoylation mutants is altered compared to wild-type 
CD81 
To study the effect of palmitoylation on CD81 function, we generated a mutant of 
human CD81 where eight intracellular and transmembrane cysteines were replaced by 
alanines or serines (CD81-8C), potentially inhibiting palmitoylation of CD81. 
Intermediate constructs lacking six or seven cysteines were also obtained, and named 
CD81-6C and CD81-7C, respectively (Fig. 2.1). These mutants were compared to a 
previously described construct with mutations in five cysteines, CD81-5C (referred to as 
triple mutant CD81 in ref. 22). A second set of constructs was generated where all of the 
substituted cysteines were replaced by alanines, and named CD81-5CA, -6CA, -7CA, and 
-8CA. 
To determine whether the introduced mutations affected CD81 expression, total 
CD81 protein levels were determined by immunoblotting using monoclonal 5A6, a 
conformation-dependent antibody recognizing a specific epitope in the large extracellular 
loop of human CD81 (Fig. 2.2A)178. Baby Hamster Kidney (BHK) cells transfected with 
the plasmids were lysed in 1% Brij-99 prior to electrophoresis and immunoblot analysis. 
Consistent with previous findings168, we observed a difference in migration between 
wild-type CD81 (wtCD81) and the mutants, which migrated faster than wild-type, 
possibly due to the absence of bound palmitate. In addition, CD81 protein levels were 
higher in cells transfected with the mutant constructs. This difference, especially between 
wtCD81 and CD81-8C, was consistently observed in multiple (more than 10) 
independent experiments using different plasmid preparations (e.g., Fig. 2.3B). 
Interestingly, mutation to serines in CD81-6C and -7C resulted in even higher CD81 
protein levels than the alanine substitutions in CD81-6CA and -7CA. There was also a 
change in the ratio between monomers and dimers (white arrow) of CD81. It has been 
reported that these dimers form after lysis when spontaneous disulfide bonds form 
between intracellular and transmembrane cysteines62. The lack of such cysteines in 
CD81-8C and -8CA would explain why no dimers were observed with these constructs 
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(Fig. 2.2A). However, the variability among the other constructs (with CD81-6C having 
the highest level of dimers) may depend on whether the specific available cysteines are 
involved in intra- or inter-molecular interactions. We observed that mutation to serine or 
alanine residues could also become a relevant factor for dimer formation (note the 
increase in dimer intensity for CD81-5CA and -7CA compared to -5C and -7C, 
respectively). The observation that the migration of the CD81 homodimers was faster 
than expected is consistent with previous results obtained with CD9 homodimers62. 
Since CD81 is mainly targeted to the plasma membrane, we examined whether 
cysteine mutagenesis affected its localization at the cell surface. BHK cells were 
transfected with the mutant constructs and the cells were stained for flow cytometry using 
αCD81 antibody 5A6 (Fig. 2.2B). In contrast to the immunoblotting results, we observed 
an overall decrease in the detection of CD81 mutant proteins compared to wtCD81. In the 
case of the serine mutants (CD81-5C, -6C, -7C, and -8C), there was a correlation between 
an increased number of mutated cysteines and reduced CD81 detection at the cell surface. 
The alanine mutants (CD81-5CA, -6CA, -7CA, and -8CA), however, had an intermediate 
phenotype, between the levels of their corresponding serine mutants and wtCD81. A 
similar pattern was observed when another mAb also specific for the large extracellular 
loop of CD81 (JS81) was used (data not shown). Furthermore, only surface protein 
detection was affected by these point mutations since all serine mutant CD81 transcript 
levels were comparable to wtCD81 as measured by real time RT-PCR (data not shown). 
Surface detection by 5A6 was also tested in COS-7 cells transiently expressing wtCD81 
and CD81-8C, and similar results were obtained (data not shown).  
To test whether the difference in protein levels seen by immunoblotting was 
independent of the antibody used, we tagged wtCD81, CD81-5C, and -8C with a V5 
epitope at their carboxyl termini. As observed with the untagged constructs, CD81-5C-
V5 and CD81-8C-V5 were detected at a higher level than wtCD81-V5 by immunoblot 
using αV5 antibody (Fig. 2.2C), but flow cytometry measurements using 5A6 showed 
reduced surface levels of CD81-8C-V5 compared to wtCD81-V5 (Fig. 2.8A). 
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Mutation of six cysteines is necessary for complete inhibition of CD81 
palmitoylation 
To analyze if palmitoylation was defective in our constructs, we biosynthetically 
labeled COS-7 cells expressing the CD81 mutants with [3H]-palmitic acid. After Brij-99 
lysis, samples were immunoprecipitated with 5A6, resolved by SDS-PAGE, and 
transferred to PVDF membranes. Duplicate membranes were then exposed to X-ray film 
or probed with 5A6. Figure 2.3C shows the level of palmitic acid incorporation in CD81 
relative to the expression of each construct (Fig. 2.3B). In contrast to an earlier report22, 
substituting only five cytoplasmic cysteines was not sufficient to completely inhibit 
CD81 palmitoylation. We observed that palmitoylation was reduced by 75% in CD81-
5C, while additional mutation of the cysteine residue at position 80 reduced 
palmitoylation to 11% of wtCD81. Further mutation of cysteines at positions 97 and 104 
did not appreciably decrease palmitoylation further. Therefore, mutation of at least six 
juxtamembrane cysteines is necessary to fully inhibit CD81 palmitoylation. 
Association of EWI-2 or CD9 with palmitoylation-deficient CD81 is impaired 
Since interactions with other molecules are critical for tetraspanin-mediated 
functions177, we performed co-immunoprecipitations to examine the effect of cysteine 
mutagenesis on CD81 associations with other tetraspanin web members. We tested the 
ability of the CD81 mutants to bind to the tetraspanin CD9 and the Ig superfamily 
member EWI-2, two proteins normally found associated with CD81177. Our results 
indicated that the amount of CD9 and EWI-2 co-immunoprecipitated by CD81 depended 
on the number of cysteines in the cytoplasmic and transmembrane domains (Fig. 2.4A 
and B). We observed a slight but consistent reduction in CD9 association to the 
palmitoylation-deficient proteins that was most pronounced when all eight cysteines were 
replaced (Fig. 2.4A). However, CD9 interaction with CD81-5C did not appreciably differ 
from wtCD81. Longer exposure of the blot revealed upper bands that were stronger when 
CD81-6C or CD81-7C were pulled down (white arrow). Similar to the bands seen in 
figure 2.2A, they may be the result of post-lysis formation of CD9 homodimers. When we 
assessed CD81 association with EWI-2, all mutated proteins co-immunoprecipitated 
EWI-2 at lower levels, with CD81-8C being the lowest (Fig. 2.4B). We also examined the 
 40 
surface levels of CD9 and EWI-2 when co-expressed with CD81-8C but did not detect 
any significant difference relative to co-expression with wtCD81 (Fig. 2.4C). In 
conclusion, the data suggest that mutating these cysteine residues affects the association 
of CD81 with CD9 and EWI-2 but does not affect the expression of CD9 or EWI-2 on the 
plasma membrane. 
CD81 protein stability remains unchanged after mutation of six or eight 
cysteines 
One possible explanation for the apparent increase in total expression of the 
mutant CD81 proteins is that the mutations affected the stability of CD81. To address 
this, we performed pulse-chase labeling on CD81-transfected BHK cells using [35S]-
methionine/cysteine. Proteins were labeled for one hour and chased for various time 
intervals. Protein stability during the next 2 to 3 days was measured for wtCD81, CD81-
6C, and -8C (Fig. 2.5). Since CD81-6C and 8C had lower radiolabeling than wtCD81 (as 
expected, due to the absence of multiple cysteines), we normalized the densitometry 
values for each protein by taking time zero as 100%. No significant change in stability 
was observed among these proteins, with each having a half-life between 12 and 22 hours 
(values estimated from four independent experiments). Additionally, we observed a small 
upward shift in wtCD81 migration in the early time points that is not apparent in CD81-
6C or -8C (Fig. 2.5, compare 0 and 1 hour to 6 hours and later). We hypothesize that this 
decrease in migration is due to the addition of palmitic acid during CD81 maturation. 
These results indicate that palmitoylation does not affect the stability of CD81, and 
alterations in protein stability cannot explain the differences observed in total protein 
expression between mutant and wtCD81. 
CD81-8C proteins are localized normally to the plasma membrane and bind to 
αCD81 antibody 5A6 normally, but their detection by 5A6 on the cell surface is 
hindered 
The decrease in CD81 mutant surface detection relative to wtCD81 as measured 
by flow cytometry (Fig. 2.2B) could reflect a defect in trafficking of the protein to the 
plasma membrane. To address this question, we surface biotinylated BHK cells 
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transfected with V5-tagged wtCD81 or CD81-8C. Biotinylated CD81 proteins were 
detected by Streptavidin pull-down followed by αV5 immunoblotting. We observed an 
increase in biotinylated CD81-8C proteins levels compared to wtCD81 (Fig. 2.6A), 
similar to the increase seen in total protein levels of CD81 mutants (Fig. 2.2A and C), 
suggesting that CD81 transport to the plasma membrane is not affected by the cysteine 
mutations. Similar results were obtained using untagged wtCD81 and CD81-8C by 5A6 
immunoblot (data not shown). 
Another possible explanation for the apparent decrease in surface expression of 
the mutant proteins by flow cytometry is a defect in 5A6 binding to the CD81 mutant 
proteins. To test this hypothesis, we performed a saturation binding assay where 
transfected BHK cells were incubated with increasing concentrations of FITC-labeled 
5A6 and analyzed by flow cytometry. From the saturation isotherm curves, we obtained 
similar KD values for both wtCD81 and CD81-8C (Fig. 2.6B), suggesting that the affinity 
of 5A6 for CD81 remains unchanged when all eight cysteines are mutated. However, the 
CD81-8C curve reached a plateau at a level (Bmax= 22.66) considerably lower than 
wtCD81 (Bmax= 52.66), indicating a reduction in the number of 5A6 binding sites on the 
surface of cells expressing CD81-8C compared to wtCD81. 
Cleavage of CD81 is altered when all eight cysteines are mutated 
When we examined the expression of V5-tagged wtCD81 and CD81-8C proteins 
by immunoblot using αV5 antibody, we observed the appearance of additional faster 
migrating immunoreactive bands when blots were exposed for a longer time: one band at 
26-28 kDa (grey arrows) and additional bands at 10-12 kDa (black arrows, Fig. 2.7A). 
Interestingly, there was a consistent difference in the amounts of these faster migrating 
bands for CD81-8C compared to wtCD81 across various cell types (Fig. 2.7A). In 
addition to the increase in full-length CD81-8C levels described above (Figs. 2.2 and 
2.3), CD81-8C-V5 proteins were characterized by an increase in the 26-28 kDa band and 
a decrease of the 10-12 kDa bands compared to wtCD81-V5. We did not observe the 
faster migrating 10-12 kDa bands on immunoblots using αCD81 antibody 5A6. This is 
consistent with these 10-12 kDa bands arising due to proteolysis of CD81; since the 10-
12 kDa fragments contain the C-terminal V5 tag, they would not be expected to include 
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the 5A6 epitope, based on their size. On the other hand, the 26-28 kDa form probably 
does not arise from this proteolysis event, since its levels correlated with those of full-
length CD81 (Fig. 2.7A). Thus, a portion of CD81 appears to be proteolytically cleaved, 
and reduced cleavage of mutant CD81 explains the apparent increase in detection of full-
length mutant CD81 by immunoblotting with either 5A6 or αV5 (Figs. 2.2, 2.3, and 2.7). 
The presence of mutant CD81 also affects CD9 processing 
Cells co-transfected with CD9-V5 (C-terminal tag) and wtCD81 or CD81-8C 
showed the presence of a faster migrating immunoreactive CD9 band around 18 kDa that 
was strikingly reduced in intensity when CD81-8C was co-expressed (Fig. 2.7B, black 
arrow), even though the levels of full-length CD9 remained unchanged (upper blot). We 
observed the same effect on CD9 when it was co-transfected with CD81-7C, -7CA, or -
8CA (data not shown). On the other hand, CD9 homodimer formation was only 
diminished when wtCD81 was co-expressed (Fig. 2.7B, white arrow), consistent with the 
decreased interaction between CD9 and CD81-8C compared to wtCD81 (Fig. 2.4). 
Brefeldin A treatment prevents CD81 cleavage 
We used brefeldin A, an inhibitor of ER-Golgi transport, to examine whether 
CD81 targeting to the Golgi or plasma membrane was required for the processing event 
observed in figure 2.7. Transfected BHK cells were treated with brefeldin A for 10 hours 
and analyzed for surface CD81 by flow cytometry using 5A6. Surface levels of both 
wtCD81-V5 and CD81-8C-V5 were reduced by similar ratios after brefeldin A 
incubation (Fig. 2.8A), indicating similar kinetics of transport to the cell surface. Similar 
results were obtained with untagged versions of these constructs (data not shown). 
However, when similarly transfected cells were assayed by immunoblotting with αV5, 
the levels of full-length wtCD81 were increased by brefeldin A treatment, while the 
levels of the 10-12 kDa bands decreased (Fig. 2.8B). Brefeldin A also had a similar effect 
on CD81-8C-V5 but it was less pronounced. The appearance of the 26-28 kDa CD81 
band was also inhibited by brefeldin A (grey arrow). Endogenous human full-length 
CD81 levels were also affected by brefeldin A treatment in HT1080 cells as determined 
by 5A6 immunoblotting (Fig. 2.8C), indicating that the observed processing of CD81 is 
not a result of protein overexpression but a bona fide cellular event. These results indicate 
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that the faster migrating forms of CD81 are due to posttranslational processing events 
that occur after CD81 enters the Golgi complex. 
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Discussion 
This study presents novel data on the effects of juxtamembrane cysteine 
mutagenesis on CD81 behavior in cells. Previous reports have used similar constructs to 
examine whether acylation had an effect on specific CD81 functions, but a thorough 
characterization of a palmitoylation-deficient CD81 has not been previously published13, 
22, 79. We found that complete inhibition of CD81 palmitoylation required mutagenesis of 
at least six juxtamembrane cysteine residues (Fig. 2.3). We detected what initially 
appeared to be reduced CD81 levels on the plasma membrane when cytoplasmic and 
transmembrane cysteines were replaced (Fig. 2.2B). This reduction was not due to a 
defect in CD81 transport to the cell surface (Fig. 2.6A), or in the affinity of αCD81 
antibody 5A6 for its epitope, which lies in the large extracellular loop of CD81 (Fig. 
2.6B). In contrast, total protein levels of the mutants, particularly CD81-8C, appeared to 
be higher than wtCD81 by immunoblotting (Fig. 2.2A and C), and surface biotinylation 
results indicated that higher amounts of CD81-8C were transported to the plasma 
membrane than wtCD81 (Fig. 2.6A). These results could not be explained by a difference 
in protein stability since wtCD81, CD81-6C, and -8C had similar half-lives (Fig. 2.5). 
However, when CD81 was C-terminally tagged with a V5 epitope, the appearance of 
faster migrating bands in immunoblots using αV5 antibody was reduced with CD81 
mutant proteins compared to wtCD81 (Fig. 2.7A). These faster migrating CD81 forms are 
presumably due to proteolytic processing occurring in the Golgi or at the plasma 
membrane since their appearance is inhibited by brefeldin A (Fig. 2.8B). Finally, the 
associations of CD81 mutant proteins with CD9 and EWI-2 were impaired compared to 
wtCD81 (Fig. 2.4). The results obtained for wild-type CD81 and CD81-8C are 
summarized in figure 2.9. Taken together, a likely explanation for these data is that the 
mutation of juxtamembrane cysteines in CD81 results in altered interactions between 
CD81 and other membrane proteins, which results in masking or covering up of CD81 
and reduced access by large molecules such as antibodies or proteases by steric 
hindrance. 
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Cysteine mutagenesis remains the most common method used to study the role of 
palmitoylation on a specific protein. Since no specific palmitoylation motif is known, 
substitution of all available cysteines is generally used to completely inhibit palmitic acid 
attachment. To generate palmitoylation-deficient CD81 proteins, other groups have 
replaced five cysteines located in the intracellular domains at positions 6, 9, 89, 227, and 
22813, 22. However, the predicted three-dimensional conformation of the second 
transmembrane domain places another cysteine (position 80) at the plasma membrane-
intracellular interface where it would be available for acylation1. Consistent with this 
model, we showed that CD81 proteins lacking only five cysteines still incorporate 25% of 
the wild-type levels of palmitic acid (Fig. 2.3). However, the contribution of cysteines 97 
and 104 to palmitoylation is unclear, since the sensitivity of the labeling assay used in 
this study cannot differentiate among CD81-6C, -7C, and -8C. Since cysteines 97 and 
104 are predicted to be embedded in the third transmembrane region1, it is possible that 
their accessibility to palmitic acid is constrained by neighboring residues and 
phospholipids. Further studies using more sensitive methods such as mass spectrometry 
should provide more precise information on the number of cysteines that are available for 
palmitoylation. 
Several groups have used this mutagenesis approach to inhibit palmitoylation in 
tetraspanins, but none have addressed the differences that could occur depending on the 
residue chosen to replace cysteines, either serines or alanines. Here, we report differences 
in apparent CD81 surface expression depending on the use of serines or alanines at 
positions 80, 89, 97, and 104, which are residues located inside or in close proximity to 
transmembrane domains (Fig. 2.2A and B). Because serine is more hydrophilic relative to 
cysteine, it could have an impact when introduced into a hydrophobic membrane 
environment by disrupting protein structure and interactions with other proteins. This 
difference might be relevant when mutagenesis of all transmembrane cysteines is needed 
to map interaction domains by cysteine-scanning mutagenesis. For example, we found an 
increase in dimer formation between CD81-7CA and CD81-7C, mutants that lack all but 
one cysteine at position 104 (Fig. 2.2A). The only difference between these two 
constructs is the amino acid used to replace all the other cysteines: only alanines (CD81-
7CA) or a mixture of alanines and serines (CD81-7C). The observation that the surface 
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detection of CD81-7CA and CD81-8CA mutants is not as severely affected as CD81-7C 
or CD81-8C (Fig. 2.2B) indicates that alterations in protein structure due to amino acid 
substitution play at least some role in our results. However, the possibility remains that 
lack of palmitoylation may also have an effect, since detection of surface CD81-7CA and 
CD81-8CA is still decreased compared to wtCD81. 
Palmitoylation is known to regulate trafficking to the plasma membrane of a 
number of integral membrane proteins (e.g., CCR5, δ opioid receptor, thyrotropin 
receptor, and histamine H2 receptor)169, 181-184. Thus, the decrease in surface detection of 
the CD81 mutant proteins by flow cytometry (Fig. 2.2B) initially led us to think there was 
a defect in protein transport to the cell surface. However, this hypothesis was refuted 
when immunoblots displayed an increase in surface biotinylated CD81-8C compared to 
wtCD81 (Fig. 2.6A), corresponding to the levels of total CD81 protein (Fig. 2.2A). We 
then considered that the affinity of αCD81 monoclonal antibody 5A6 for the CD81 
mutant proteins might be reduced, which would explain the decreased detection by flow 
cytometry. However, 5A6 binding to both wtCD81 and CD81-8C showed similar KD 
values (Fig. 2.6B). One difference between these assays is the use of biotin, a relatively 
small molecule (0.5 kDa), versus an antibody (150 kDa) to detect surface expression. 
Therefore, to explain these apparently contradictory results, we propose that these CD81 
mutant proteins are expressed and transported to the cell surface normally, but once at the 
surface they become inaccessible to bulky proteins such as antibodies. Either the lack of 
palmitoylation or structural alterations due to amino acid substitutions, or a combination 
of both factors, may cause CD81 to be displaced to a membrane compartment where it is 
surrounded by large neighboring proteins, thus preventing 5A6 binding by steric 
hindrance but still allowing access to biotin. It has been shown that palmitoylation 
induces translocation of CD81 to lipid rafts171. Additionally, association of the CD81 
mutant proteins with CD9 and EWI-2 is decreased compared to wtCD81 (Fig. 2.4A and 
B), supporting the hypothesis that when these cysteines are mutated, the protein network 
surrounding CD81 is affected. However, palmitoylation-deficient CD9 and CD151 
proteins have been shown to remain in TEMs similar to their wild-type counterparts. It is 
possible that the methodology used to detect membrane microdomains localization is not 
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precise enough to detect subtle changes in protein displacement around the plasma 
membrane. 
Another initially puzzling set of results was the apparent increase, using 
immunoblotting, in total CD81 protein levels when cysteines were mutated (Fig. 2.2A 
and C). We showed that protein stability was not affected in our mutants (Fig. 2.5), and 
levels of mRNA expressed from the serine mutant and wtCD81 constructs were shown to 
be similar (data not shown). Then, we observed additional faster migrating bands on 
immunoblots using an antibody specific for an epitope tag located at the C-terminus of 
CD81 (Fig. 2.7A), adding a new level of complexity to CD81 expression. An increase in 
full-length CD81 was observed when cells were treated with brefeldin A, which 
correlated with a decrease in the faster migrating CD81 bands. Thus, changes in full-
length CD81 levels do not necessarily correspond to changes in total protein expressed; 
they may instead reflect disparities in CD81 processing. The functional significance of 
these faster migrating CD81 forms remains to be understood. Other groups have used 
brefeldin A (at similar concentrations) and reported no difference in levels of endogenous 
tetraspanins including CD81170, 175. However, when we tested the effect of brefeldin A on 
endogenous CD81 in a human cell line (HT1080), we observed an increase in full-length 
CD81 levels (Fig. 2.8C), indicating that a similar type of processing occurs under 
physiological conditions. To our knowledge, the presence of similar faster migrating 
bands on tetraspanin immunoblots has not been previously reported. It should be noted 
that most tetraspanin-specific antibodies would not detect these bands, since they usually 
bind at the large extracellular loop. 
The decreased processing of CD81-8C (Fig. 2.7A) also supports our hypothesis 
that palmitoylation-deficient CD81 proteins are surrounded by different proteins 
compared to wtCD81. Indeed, this new environment may bring less or different proteases 
in close proximity to CD81, or inhibit access to CD81 by steric hindrance, thus reducing 
the proportion of processed forms. The reduction in the intensity of a similar faster 
migrating CD9 band and increase in CD9 homodimerization when CD9 was co-
expressed with CD81-8C compared to wtCD81 might also be the result of a change in 
protein interactions surrounding CD9 and CD81 (Fig. 2.7B). At this time we cannot 
completely distinguish between the effects of inhibiting palmitoylation and possible 
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conformational effects due to the mutation of juxtamembrane cysteines in CD81. Thus, it 
remains possible that palmitoylation may contribute to the assembly of the tetraspanin 
network, but our results illustrate that caution must be used when interpreting the results 
of such mutational approaches on protein function. 
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Figures 
 
 
 
 
Figure 2.1 Location of mutated cysteines in CD81 mutants 
The CD81 mutant constructs used in this study were obtained by replacing cysteines 
present in the cytoplasmic or transmembrane (illustrated by cylinders) domains with 
alanines or serines as indicated via site-directed mutagenesis (wt, wild-type). Residues in 
bold indicate ones that were altered in comparison to the construct immediately above. 
The top line indicates the positions of the mutations.† 
                                                
† CD81-6C, -7C, and -8C constructs were generated by Taryn R. Penabaz. 
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Figure 2.2 Expression of CD81 mutant proteins in BHK cells 
BHK cells were transfected with the indicated CD81 constructs and analyzed for total 
CD81 levels by immunoblotting with the αCD81 mAb 5A6 after lysis with 1% Brij-99 
(A), or for surface CD81 expression by flow cytometry using 5A6 (B). V5-tagged 
wtCD81, CD81-5C, and CD81-8C were similarly tested for expression by 
immunoblotting (C). Note that wtCD81 is barely visible at this exposure. In panel A, a 
longer exposure of the same blot is presented below to show dimer formation (white 
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arrow). In panel B, the values shown are means from 5 independent experiments 
normalized relative to wtCD81 levels (100%). Error bars indicate standard error of the 
mean (SEM). V, vector; MFI, mean fluorescence intensity. 
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Figure 2.3 Palmitoylation levels of CD81 mutants 
COS-7 cells transfected with the CD81 constructs were starved and labeled overnight 
with [3H]-palmitic acid. Samples were then lysed with 1% Brij-99 and 
immunoprecipitated with αCD81 mAb 5A6. Following SDS-PAGE and transfer to 
PVDF membranes, samples were exposed to autoradiography for one week (A). As a 
control, the level of CD81 was assayed by immunoblotting duplicate membranes using 
5A6 (B). Relative palmitoylation values were obtained by normalizing the amount of 
[3H]-palmitic acid in panel A to the total amount of CD81 expressed in panel B, as 
assessed by densitometry (C). Palmitoylation of wtCD81 was set at 100%.‡ 
                                                
‡ This experiment was performed by Taryn R. Penabaz. 
 53 
 
 54 
Figure 2.4 Association of CD81 mutants with CD9 and EWI-2 
BHK cells transiently co-expressing the CD81 constructs and CD9-V5 or EWI-2-V5 
were lysed with 1% Brij-99, and CD81 proteins were immunoprecipitated with αCD81 
mAb 5A6. Immunoblots were probed with αV5 antibody to assess the co-
immunoprecipitation of CD9-V5 (A) or EWI-2-V5 (B). Relative amounts of CD9 and 
EWI-2 in the immunoprecipitated material or the supernatant were obtained by 
densitometry. A longer exposure of the blot in (A) is presented below to show dimer 
formation (white arrow). Surface detection levels of CD9 and EWI-2 when co-expressed 
with wtCD81 or CD81-8C were assessed by flow cytometry using 5A6 (open bars) and 
αEWI-2 or αCD9 (closed bars) (C). 
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Figure 2.5 Stability of wtCD81, CD81-6C, and CD81-8C proteins 
BHK cells expressing wtCD81, CD81-6C, or CD81-8C were methionine/cysteine-
starved, pulsed with [35S]-methionine/cysteine, and chased for the indicated time periods 
(hours). Following lysis and CD81 immunoprecipitation, samples were resolved by SDS-
PAGE and gels were exposed to X-ray film. CD81 immunoblots were carried out using 
the same samples to show CD81 expression levels from each construct. Densitometry 
values were normalized by setting the value obtained for 0 hours at 100% for each 
protein. 
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Figure 2.6 Surface detection of wtCD81 and CD81-8C proteins by biotinylation and 
αCD81 mAb 5A6 binding 
BHK cells expressing V5-tagged wtCD81 or CD81-8C were surface biotinylated, lysed, 
and biotinylated proteins were pulled down with Streptavidin beads. Immunoblots were 
probed with αV5 antibody (A). 5A6 binding to CD81 was assayed by incubating BHK 
cells expressing wtCD81 or CD81-8C proteins with increasing concentrations of 5A6 
followed by flow cytometry analysis (B). In panel B, data points represent the mean of 
two independent experiments (± SEM). 
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Figure 2.7 Processing of wtCD81 and CD81-8C proteins, and of CD9 when co-
expressed with wtCD81 or CD81-8C 
BHK, 293, or HT1080 cells transfected with V5-tagged wtCD81 or CD81-8C were lysed, 
and CD81 protein expression patterns were assessed by immunoblotting using αV5 
antibody (A). Faster migrating forms of CD81 are indicated by grey and black arrows. 
Two exposures of the same BHK immunoblot are presented to show the differences 
between wtCD81 and CD81-8C in the levels of full-length CD81 (upper left panel) and 
the faster migrating forms of CD81 (upper right panel). In panel B, Brij-99 lysates from 
BHK cells, co-transfected with CD9-V5 and wtCD81 or CD81-8C, were analyzed for 
CD9 expression by αV5-antibody immunoblot. Faster migrating forms of CD9 and CD9 
homodimers are indicated by black and white arrows, respectively. A shorter exposure of 
the same blot (upper panel) shows the levels of full-length CD9 monomers. 
 59 
 
 
 
 
 60 
Figure 2.8 Effect of brefeldin A on wtCD81, CD81-8C, and endogenous CD81 
protein processing 
BHK cells transiently expressing V5-tagged wtCD81 or CD81-8C were treated with 
ethanol carrier (control cells) or brefeldin A (10 µg/ml) for 10 hours. Cells were analyzed 
by flow cytometry using αCD81 mAb 5A6 (A), or by αV5-antibody immunoblotting 
following Brij-99 lysis (B). In panel B, a longer exposure is presented (right panel) to 
show the CD81 processed forms (grey and black arrows). Human HT1080 cells were 
similarly treated with or without brefeldin A and endogenous human CD81 levels were 
analyzed by 5A6 immunoblotting (C). Levels of 14-3-3β were analyzed as a loading 
control. In panel A, flow cytometry percentages are means from 2 independent 
experiments normalized relative to wtCD81 control levels (100%) (± SEM). MFI, mean 
fluorescence intensity; CTRL, control; BFA, brefeldin A treatment. 
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Figure 2.9 Summary of the results obtained for wtCD81 and CD81-8C 
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CHAPTER 3 - Characterization of Human and Mouse   
Tspan-2 
Introduction 
Tetraspanins are membrane proteins best defined by their structural features: four 
transmembrane domains, two extracellular loops of unequal size, and short cytoplasmic 
regions. Their function relies on the association with multiple proteins in a plasma 
membrane network called the tetraspanin web. The protein content of this network varies 
depending on the cell type, thus allowing tetraspanins to influence diverse cellular 
processes including B cell activation, tumor progression, viral infection, and bladder 
permeability. The tetraspanin web is thought to orchestrate associations among proteins 
to bring together proteins required for specific functions, thereby facilitating signaling 
pathways86, 177. Most, if not all, multicellular organisms express several tetraspanins. For 
example, 33 different tetraspanins are found in humans. However, less than half of 
human tetraspanins have been studied in detail. Included among these uncharacterized 
tetraspanins is Tspan-2. 
There is only one previous major report focusing primarily on mammalian Tspan-
2. Birling et al. discovered Tspan-2 in a subtractive cDNA library designed to find genes 
highly expressed in rat oligodendrocytes185. Northern blots showed that rat Tspan-2 
expression was limited to the nervous system185. By using immunofluorescence, the 
authors confirmed that Tspan-2 is enriched in oligodendrocytes185. By extrapolating from 
known tetraspanin functions, it was speculated that Tspan-2 might participate in the 
communication between oligodendrocytes and the axons they surround185. Not 
surprisingly, CD9 was shown to precipitate Tspan-2 from rat brain tissue, suggesting that 
Tspan-2 might also belong to the tetraspanin web186. However, due to the lack of 
functional data, it remains too early to assign a particular role to Tspan-2. A different 
group did not find any Tspan-2 sequences in human EST libraries from nervous tissue187. 
However, because this study only included four ESTs, it is not possible to make any 
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meaningful conclusions. Indeed, at the time this dissertation was written, UniGene lists 
10 human Tspan-2 ESTs in brain tissue, whereas none are found in the nerve pool. 
Finally, Tspan-2 was found in three different screens: two screens linked to tumor 
progression (breast and squamous cell cancers) and one searching for genes downstream 
of angiotensin II (a hormone linked to heart failure through its stimulation of cardiac 
remodeling)188-190. These screens indicate that human Tspan-2 is expressed outside of the 
nervous system, unlike the rat homolog, and hint to a possible role in tumor progression. 
Interestingly, several tetraspanins are known as metastasis suppressor genes, and they can 
influence cellular processes such as motility, adhesion, and proliferation—key events in 
the development of cancer191. Thus, Tspan-2 might have a similar role. 
Here, we analyzed the expression of human and mouse Tspan-2, the N-
glycosylation of human Tspan-2, and association with the tetraspanin CD81 in order to 
further characterize this relatively unknown tetraspanin. 
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Experimental Procedures 
Cell lines, antibodies, and plasmids 
Baby Hamster Kidney (BHK-21) cells were generously provided by Carol Blair 
from Colorado State University. Human embryonic kidney 293 cells were obtained from 
Scott C. Todd (Kansas State University). Cell lines were maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% heat-inactivated fetal bovine serum 
(FBS). Anti-CD81 monoclonal antibody (5A6) was obtained from Scott C. Todd and its 
specificity for human CD81 has been described previously178. Anti-V5-HRP antibody 
was obtained from Invitrogen (Carlsbad, CA). Human V5-tagged human and mouse 
Tspan-2 constructs were generated by cloning the corresponding cDNAs into 
pcDNATM3.1/V5-His TOPO® vector (Invitrogen). 
 
Site-directed mutagenesis and transfection 
The construct N139Q was obtained by mutating asparagine 139 to a glutamine 
residue using human Tspan-2 as a template and the QuikChange® Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). The construct was sequenced to verify the 
substitution and to assure other nonspecific mutations did not occur. 
BHK and 293 cells were transfected with different plasmids as indicated using 
LipofectamineTM 2000 (Invitrogen) according to the directions of the manufacturer. 
 
Peptide: N-Glycosidase F treatment 
Transfected cells were detached with 0.02% EDTA and treated with Glycoprotein 
Denaturing Buffer (0.5% SDS, 0.4 M DTT) diluted 1/10 in water at 100 ºC for 10 min. 
G7 Reaction Buffer (50 mM sodium phosphate), NP-40, and PNGase F (New England 
Biolabs, Ipswich, MA) were added, and samples were incubated overnight at 37 ºC 
(PNGase F was replaced with water in control samples). Tspan-2 expression was 
analyzed by immunoblotting as described below. 
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Immunoprecipitation 
Cells were detached with 0.02% EDTA and lysed for one hour at 4 ºC in lysis 
buffer (150 mM NaCl, 20 mM Tris pH 7.5, 5 mM MgCl2, 10 units/ml aprotinin, 1mM 
PMSF, and 1 µg/ml pepstatin A) containing 1% Brij-99 (Sigma-Aldrich). The insoluble 
material was removed by centrifugation at 21,000g for 15 min at 4 ºC. The antibody 
(5A6) was captured on Protein G-Sepharose® beads (Sigma-Aldrich) for one hour. After 
washing off the excess antibody, the lysates were added to the antibody-bead mixture and 
left rotating overnight at 4 ºC. Suspensions were centrifuged at 2,300g for 5 min at 4 ºC, 
the supernatants were collected, and the pellets were washed twice with lysis buffer 
containing 1% Brij-99, separated by SDS-PAGE under non-reducing conditions, and 
transferred to an Immobilon-P membrane (Millipore, Billerica, MA). 
 
Immunoblotting 
Proteins immobilized on PVDF membranes were blocked for one hour at 4 ºC in 
Tris-buffered saline with 0.1% Tween-20 (TBS-T) containing 5% non-fat milk. For V5 
detection, anti-V5-HRP antibody was diluted at 1:5,000 in TBS-T containing 1% non-fat 
milk for 90 min at room temperature. All blots were visualized by applying SuperSignal® 
West Pico Chemiluminescent Substrate (Pierce Biotechnology) and exposing to X-ray 
film. 
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Results and Discussion 
Human and mouse Tspan-2 have different electrophoretic migration patterns as 
detected by immunoblotting 
Sequence analysis of Tspan-2 shows that it is closely related to tetraspanins CD9 
and CD81 (Fig. 3.1A). Amino acid identity percentages are of 39% and 46% for human 
Tspan-2/CD81 and Tspan-2/CD9, respectively. However, although CD9 and CD81 have 
been well studied, little is known about Tspan-2. To investigate the expression of human 
and mouse Tspan-2 in mammalian cell lines, we generated constructs for both of them 
having a V5 epitope tag at the C-terminus. Even though the sequences for human and 
mouse are very similar (Fig. 3.1B), we observed differences in the migration of the two 
proteins as seen by αV5 immunoblot (Fig. 3.2A). In particular, an additional lower band 
running around 27 kDa was observed for mTspan-2. The 38-kDa band observed for both 
proteins is likely to correspond to full-length Tspan-2. However, the expected size of 
Tspan-2 with the V5 tag is 28 kDa. Thus, we hypothesized that the 38-kDa proteins may 
be N-glycosylated forms of Tspan-2 since both human and mouse homologs have a 
conserved putative N-glycosylation site in the large extracellular loop (LEL; Fig. 3.1B). 
Interestingly, Birling et al. reported a single band of ~25 kDa for rat Tspan-2 by 
immunoblotting using a Tspan-2-specific antibody185. This antibody was generated 
against a peptide corresponding to a portion of the rat Tspan-2 LEL, located C-terminal 
to the CCG motif. The expected size of endogenous rat Tspan-2 is 24 kDa. Therefore, the 
difference in size between expected and experimental Tspan-2 was much smaller using 
the rat Tspan-2-specific antibody compared with our results. One possibility would be 
that this antibody only targets unglycosylated Tspan-2, and its epitope might be masked 
by the glycosylation of Tspan-2. Supporting this idea, we showed that removal of N-
linked glycans form hTspan-2 increases its migration by at least 5 kDa (Fig. 3.3). 
However, this discrepancy might be due to a species-dependent difference in 
glycosylation patterns. Indeed, the 27-kDa band present only in the mTspan-2 lane 
migrates faster than unglycosylated full-length Tspan-2 (Fig. 3.3). Mutation of residues 
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that are different between human and mouse Tspan-2 might be helpful to resolve this 
question. 
Differences in banding patterns on immunoblots also occurred when comparing 
expression between two cell lines: hamster fibroblasts (BHK) and human epithelial cells 
(293) (Fig. 3.2B). The major difference was the appearance of an additional band of ~26 
kDa in both human and mouse proteins when transfected in 293 cells. Also, the migration 
of putative full-length Tspan-2 seemed slightly increased in 293 cells (see also Fig. 3.3 
and 3.4). The migration of Tspan-2 remained unaltered under reducing conditions 
although there was a decrease in overall detection (Fig. 3.2A). 
Human Tspan-2 is N-glycosylated at residue 139 
The presence of two major bands in the case of mouse Tspan-2 led us to 
hypothesize that they may be glycosylated and unglycosylated forms of Tspan-2. Indeed, 
sequence analysis identified a putative N-glycosylation site at asparagine 139 in both 
human and mouse homologs (Fig. 3.1). Treatment with the glycosidase PNGase F 
resulted in a decrease of Tspan-2 protein size as detected by αV5 immunoblotting (Fig. 
3.3A). However, the 27-kDa band of mTspan-2 seen in untreated cells ran slightly faster 
than unglycosylated full-length mTspan-2, and it was also PNGase F-sensitive, 
suggesting it is not unglycosylated mTspan-2 as first hypothesized. Mouse Tspan-2 might 
undergo a different type of maturation process in addition to N-glycosylation. 
The location of the glycosylation site to asparagine 139 was confirmed by 
substitution to a glutamine (construct N139Q) in the human Tspan-2 protein. N139Q 
protein migrated at a similar level relative to unglycosylated hTspan-2 (~30 kDa; 
compare Fig. 3.3A and B). Interestingly, when expressed in 293 cells, the ~26 kDa band 
seen in wild-type hTspan-2 was not visible for the N139Q mutant, suggesting that 
glycosylation of hTspan-2 might affect protein processing. 
Association of human Tspan-2 with CD81 is N-glycosylation-independent 
To begin examining the participation of hTspan-2 in the tetraspanin web, we 
tested its association with human CD81 by co-immunoprecipitation assays. As expected, 
we found that hTspan-2 was able to bind CD81 under conditions that do not disrupt the 
tetraspanin web (Brij-99) (Fig. 3.4). Strikingly, no hTspan-2 was precipitated by CD81-
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8C, a CD81 mutant protein lacking eight juxtamembrane cysteines—potential sites for 
palmitoylation (Fig. 3.4A). However, no hTspan-2 could be detected in the unbound 
fraction (supernatant). We think this is due to a low efficiency in Tspan-2 transfection; 
the small amount of Tspan-2 protein in cell lysates might be too dilute to be detected 
(only a small aliquot of the supernatant is used for immunoblotting). On the other hand, 
Tspan-2 protein in the immunoprecipitated samples is very concentrated and therefore, 
easier to detect. Repeating this experiment with more concentrated protein and/or more 
antibody will be necessary to confirm these results. Palmitoylation is an important post-
translational modification for the assembly of the tetraspanin web. Our result is in 
agreement with previous reports showing a decrease in tetraspanin-tetraspanin 
associations when palmitoylation sites were mutated168, 170, 172, 173. Nevertheless, a 
complete inhibition of these associations has not been reported, emphasizing the 
necessity to repeat this experiment with appropriate controls. 
Interestingly, binding of hTspan-2 to endogenous CD81 from 293 cells was not 
inhibited by a lack of N-glycosylation: N139Q was able to bind CD81 as efficiently as 
wild-type hTspan-2 (Fig. 3.4B). Additionally, we did not observe the lower ~ 26 kDa 
hTspan-2 band (usually present in 293 cell lysates) in the material precipitated by CD81 
(Fig. 3.4B). To our knowledge, this is the first report that examined the role of 
glycosylation in a tetraspanin-tetraspanin association. Surprisingly, although most 
tetraspanins have putative N-glycosylation sites, few reports have been focused on the 
influence this post-translational modification can exert on tetraspanin function. CD82 N-
glycosylation was reported to impair CD82 interaction with integrin α5162. Our findings 
suggest that glycosylation of a tetraspanin may not be required for binding to other 
tetraspanins. Future experiments with other tetraspanins will confirm whether or not this 
property can be extrapolated to the rest of the superfamily. The tetraspanin LEL is not 
always necessary for tetraspanin-tetraspanin associations; instead, it appears that the 
transmembrane and cytoplasmic (via palmitoylation) domains can facilitate this 
binding25. This would explain why the addition of glycans in the LEL of Tspan-2 did not 
affect its binding to CD81. On the other side, the association between tetraspanins and 
specific binding partners relies more often on the proper structure of the LEL (as may be 
the case for the CD82/α5 interaction). Thus, the presence of bulky carbohydrate groups 
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attached to the LEL is likely to influence these protein-protein interactions. Binding 
partners specific to Tspan-2 are yet to be discovered; nevertheless, this hypothesis can be 
tested by mutating putative N-glycosylation sites of well-known tetraspanins and 
examine how they interact with binding partners. 
Conclusion 
In summary, we showed that the migration of Tspan-2 on SDS-PAGE could vary 
depending on species (human vs. mouse Tspan-2) and cell type, suggesting changes in 
the maturation of Tspan-2. Interestingly, the electrophoretic migration of CD82—a 
tetraspanin with three N-glycosylation sites—also depends on the cell type studied120. 
This is thought to be due to a differential glycosylation of CD82. We confirmed that N-
glycosylation of Tspan-2 occurs at a single site in the LEL: asparagine 139. More 
importantly, we found that the Tspan-2 association with another tetraspanin, CD81, 
appeared to be independent of Tspan-2 glycosylation status. Therefore, these findings 
provide a starting ground for a more complete characterization of Tspan-2. 
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Figures 
 
 
 
Figure 3.1 Sequence alignment of mammalian Tspan-2 proteins 
The predicted amino acid sequence of human Tspan-2 was aligned with those of human 
CD9 and CD81 (A), or with mouse and rat Tspan-2 (B). Alignments were obtained by 
using ClustalW and BoxShade (www.ch.embnet.org). Grey and black boxes correspond 
to similar and identical amino acids, respectively. Green boxes indicate the conserved 
cysteine residues that form disulfide bonds in the large extracellular loop. The orange box 
represents a putative N-glycosylation site. 
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Figure 3.2 Expression of human and mouse Tspan-2 
BHK cells transfected with control GFP, human Tspan-2 (hTsp2), or mouse 
Tspan-2 (mTsp2) were lysed with 1% Triton X-100 and analyzed under non-reducing (- 
DTT) and reducing (+ DTT) conditions for Tspan-2 expression by αV5 immunoblotting 
(A). Human and mouse Tspan-2 were expressed in BHK and 293 cells and analyzed as in 
panel A (non-reducing conditions) to determine differences in expression patterns 
between the two cell lines (B). In panel A, a longer exposure is shown below. 
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Figure 3.3 N-glycosylation of human and mouse Tspan-2 
BHK cells transfected with human Tspan-2 (hTsp2), mouse Tspan-2 (mTsp2), or 
vector control (V) were treated with PNGase F and analyzed for Tspan-2 expression by 
αV5 immunoblotting (A). The expression pattern of the N139Q protein was compared to 
hTsp2 and mTsp2 in BHK and 293 cells lysed with 1% Brij-99 by αV5 immunoblotting 
(B). 
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Figure 3.4 Association of human Tspan-2 and N139Q with CD81 
BHK cells were co-transfected with human Tspan-2 (hTsp2) and vector (V), wild-
type CD81 (wt81), or CD81-8C (8C; having eight juxtamembrane cysteines mutated), 
and lysed with 1% Brij-99. CD81 was precipitated using αCD81 mAb 5A6 and 
associated Tspan-2 was detected by αV5 immunoblot (A). Input and supernatant samples 
represent aliquots of pre-immunoprecipitation lysates and post-immunoprecipitation 
unbound proteins, respectively. 293 cells were transfected with GFP, hTsp2, and N139Q, 
lysed with 1% Brij-99, and endogenous human CD81 was precipitated using 5A6. 
Samples were then analyzed for Tspan-2 detection as described in A (B). 
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CHAPTER 4 - Conclusion 
Almost two decades of continuing efforts have led to a clearer picture explaining 
how the tetraspanin web is organized. The field has reached the point where it can tackle 
the complex and exciting challenge of viewing the tetraspanin web as a highly dynamic 
network, and study how it can be regulated. Being able to regulate the tetraspanin web 
will become a powerful tool since it would have many implications as suggested by the 
numerous cellular functions that tetraspanins can influence. Recently, palmitoylation has 
emerged as a major regulatory mechanism for tetraspanins. In addition, most tetraspanins 
can be glycosylated, thereby providing another method to change the molecular 
properties of tetraspanins. In chapter two, we described the characterization of a set of 
CD81 mutant proteins with mutations in five, six, seven, or eight juxtamembrane 
cysteines—potential palmitoylation sites. Overall, the various effects observed with these 
mutant proteins are likely the result of a redistribution of the protein environment 
surrounding CD81. These changes in protein associations are consistent with previous 
findings from other groups. In particular, tetraspanin-tetraspanin associations are 
impaired when juxtamembrane cysteines are mutated. These interactions are crucial for 
the formation of the tetraspanin web. However, many questions remain to be answered. 
Interestingly, there seems to be two types of palmitoylation—constitutive and 
inducible—as seen with CD81 function in the B cell coreceptor. Is it possible to switch 
tetraspanins on or off depending on their palmitoylation levels? What is the difference 
between constitutive and inducible palmitoylation? Most of the studies on tetraspanin 
palmitoylation have used site-directed mutagenesis to substitute juxtamembrane 
cysteines, thus only examining constitutive palmitoylation. To investigate inducible 
palmitoylation, specific inhibitors—mainly 2-bromopalmitate (2-BP)—have been used. 
However, they present several drawbacks. First, these chemicals inhibit non-specifically 
the palmitoylation of all cellular proteins. Therefore, it is harder to make definite 
conclusions on the regulation of the protein of interest. The effect of CD81 
palmitoylation in the microdomain stability of the B cell coreceptor was concluded 
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because the lipid raft distribution of the B cell coreceptor regulated by CD81 and an 
increase in CD81 palmitoylation both occur upon coligation of the BCR with the B cell 
coreceptor and are inhibited by 2-BP. However, these results do not exclude the 
possibility that palmitoylation of additional proteins are important on the B cell 
coreceptor localization to lipid rafts. Second, 2-BP has been reported to have other effects 
aside form inhibiting protein palmitoylation192. Intriguingly, 2-BP treatment did not 
impair tetraspanin-tetraspanin interactions like palmitoylation-deficient tetraspanins. It 
was proposed that palmitoylation facilitates the early events of tetraspanin web assembly, 
and once it is established, palmitoylation is no longer required. Thus, results obtained 
from experiments using such inhibitors should be taken with a grain of salt. 
An additional tool to study tetraspanin palmitoylation has been provided by the 
discovery of DHHC2 as a palmitoyl acyl transferase able to palmitoylated CD9 and 
CD151. More importantly, this enzyme seems specific to CD9 and CD151. Thus, it is 
possible to regulate the palmitoylation of these tetraspanins by overexpressing or 
downregulating DHHC2 expression levels. In this way, palmitoylation of CD9 and 
CD151 was found to be important for binding to other tetraspanins, thereby confirming 
the results obtained by site-directed mutagenesis. Does DHHC2 palmitoylate other 
tetraspanins? Are there additional palmitoyl acyl transferases responsible for tetraspanin 
palmitoylation? As more knowledge is gained in the field of enzymatic palmitoylation, 
more tools will become available to artificially disrupt the tetraspanin web and study the 
functional consequences. In addition, it would be interesting to identify enzymes 
responsible for removing palmitate from tetraspanins (palmitoyl thioesterases), and which 
pathways act to control the activity of such enzymes. Therefore, each approach used to 
investigate tetraspanin palmitoylation has its own advantages and it is the combination of 
all these methods that will make it possible to finally understand how the tetraspanin web 
dynamically orchestrates plasma membrane proteins. 
Glycosylation of tetraspanins, on the other hand, has received little attention. 
However, the presence of multiple carbohydrates on the LEL of a tetraspanin is likely to 
alter its molecular interactions. More importantly, although tetraspanins share a similar 
structure, N-glycosylation sites do not appear to be conserved among members of the 
superfamily, hinting toward a possible way the cell can distinguish one tetraspanin from 
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another. This is illustrated by the differences in the glycans attached to tetraspanin 
uroplakins UP Ia and Ib, which explain why only UP Ia serves as a receptor for 
Escherichia coli infection. Similar studies need to be done on other tetraspanins. 
Interestingly, glycosylation of CD82 is thought to vary depending on cell type. This 
might provide tetraspanins a way to play different tissue-specific roles. Another question 
is the effect of glycosylation on protein interactions within the tetraspanin web. Does 
glycosylation influence tetraspanin primary, secondary, or all types of interactions? Our 
results presented in chapter three indicate that tetraspanin-tetraspanin associations remain 
unchanged. However, this needs to be confirmed by future studies. 
As is often the case in science, new discoveries seem to lead to more questions 
than answers. Tetraspanin palmitoylation is a good example. The excitement brought by 
the possibility that tetraspanins could be regulated post-translationally pointed the field 
toward an unexpected path filled with new obstacles. More importantly, it is the power of 
collaboration that advances scientific knowledge by bringing different perspectives 
together—such as using palmitoylation-deficient proteins, treating with inhibitors, or 
altering DHHC2 expression to understand the role of palmitoylation. Therefore, it has 
been a privilege for me to add this humble contribution to the field of tetraspanins. My 
results represent a small puzzle piece that I hope will help in elucidating how tetraspanins 
undertake the incredible challenge of organizing the plasma membrane. 
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